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CHAPTER 1 
Methionine sulfoximine as an investigational new drug: discovery, known biochemical 
targets, and uses in treating models of human disease 
The work presented here is an expansion of recently published work: 
Brusilow WSAB, Peters TJ. Therapeutic effects of methionine sulfoximine in multiple diseases 
include and extend beyond inhibition of glutamine synthetase. (2017). Expert Opin Ther Targets. 
21(5):461-469. doi: 10.1080/14728222.2017.1303484. 
Glutamate and glutamine facilitate nitrogen metabolism in living organisms 
Nitrogen is an essential ingredient for life, comprising a significant portion of 
macromolecules in organic life forms. Although approximately 78% of Earth’s atmosphere 
consists of nitrogen gas (N2), most organisms lack the ability to convert inert nitrogen gas and 
other inorganic nitrogen species into bioavailable forms. The nitrogen cycle begins largely within 
soil, in a symbiotic niche near the vicinity of plant roots known as the rhizosphere. Certain 
prokaryotes within the rhizosphere contain specialized enzyme nitrogenases that form ammonium 
ions by reducing N2. Plants and other organisms use ammonia to synthesize amino acids, which 
serve as building blocks of protein and nucleic acids. Therefore, most organisms rely on nitrogen 
acquired through the diet. 
In humans, dietary nitrogen exists in the form of amino acids, protein, and free ammonia 
generated from gastrointestinal (GI) bacteria. Dietary nitrogen compounds are centralized through 
the reactions of glutamine synthetase, glutamate dehydrogenase, and glutaminase, which 
enzymatically interconvert glutamate with glutamine. Glutamate and glutamine can both act as 
nitrogen donors, and glutamate can also act as a nitrogen acceptor. Unlike carbon, which can be 
stored for energy in the forms of glycogen and triglycerides, the human body is not equipped to 
2 
 
 
 
store excess nitrogen that is not already incorporated into functional molecules such as protein, 
DNA, and RNA. Additionally, ammonium ions are slightly basic, with a pKa of 9.24. Therefore, 
glutamate and glutamine formation comprise the major pathway of ammonia detoxication in all 
tissues except for liver, which contains a full set of urea cycle enzymes. Lastly, these amino acids 
provide a safe and effective system for transporting nitrogen to distal tissues for either utilization 
or excretion.  
In addition to controlling the flow of nitrogen throughout the body, both glutamine and 
glutamate are centrally involved in many reactions of both intermediary metabolism and 
neurotransmission. Glutamate is the major excitatory neurotransmitter in the brain and is also the 
amino acid donor in transamination reactions that move amino groups between carbon skeletons 
containing α-keto groups. Glutamine is the amino acid present in the highest concentration in the 
blood and body, except for in the brain where its concentration is second to that of glutamate. 
Glutamine is a substrate in the first reaction of both purine and pyrimidine synthesis pathways. As 
keystone molecules of nitrogen and carbon metabolism, deviations from homeostatic glutamate 
and glutamine concentrations pose significant physiological consequences, which are discussed in 
subsequent sections. The nitrogen cycle discussed in this section is summarized in Figure 1. 
Methionine sulfoximine inhibits glutamine synthetase 
Methionine sulfoximine (MSO) is an amino acid (MW: 180 grams/mole) that is structurally 
analogous to methionine, glutamine, and glutamate.  In mammals, it is an inhibitor of glutamine 
synthetase and γ-glutamylcysteine synthetase, the first step in glutathione synthesis. MSO has been 
best characterized as a mechanistic based inhibitor of glutamine synthetase(1-3). The reaction 
carried out by glutamine synthetase, as well as the mechanism of MSO inhibition is depicted in 
Figure 2. Glutamate and ATP bind to specific positions within the active site. ATP is hydrolyzed 
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by the enzyme, and the gamma phosphate molecule is transferred to the epsilon oxygen of 
glutamate to form γ-glutamyl phosphate. γ-glutamyl phosphate is a high energy intermediate; the 
energy stored in the phosphate bond is harnessed by the enzyme to form glutamine by condensing 
ammonia with the intermediate. 
Figure 1. Overview of the nitrogen cycle. Atmospheric nitrogen gas diffuses into soil where it 
encounters various prokaryotes within the vicinity of plant roots. Nitrogen fixing bacteria contain 
nitrogenase enzymes that reduce atmospheric nitrogen to ammonia. Nitrifying and denitrifying 
bacteria also act on ammonia to create other nitrogen species such as nitrate and, nitrite, which can 
be recycled back into nitrogen gas. NH3 is taken up by plants and other organisms and incorporated 
into the amino acids glutamate and glutamine, which serve as precursor molecules for biochemical 
reactions involving nitrogen.  
GDH = glutamate dehydrogenase; GLS = glutaminase; GS = glutamine synthetase; 
N2 = nitrogen gas; NH3 = ammonia; rxn = reaction. 
MSO competes with glutamate for binding to the active site of glutamine synthetase. Upon 
binding of MSO and ATP, the enzyme transfers the gamma phosphate of ATP to the imine nitrogen 
of MSO, forming MSO phosphate. MSO phosphate binds very tightly to the enzyme and cannot 
be released from the active site, causing irreversible inhibition. Therefore, MSO may be referred 
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to as a “suicide inhibitor” because inhibition is mediated through enzyme catalysis. Typical of 
mechanistic based inhibitors, the cell must synthesize new enzyme to regain glutamine synthetase 
activity. Rats treated with MSO take 7-10 days to fully regain glutamine synthetase activity(4). 
The Ki for MSO inhibition of glutamine synthetase differs from species to species, and the 
activity of tissue specific isoforms also show varied responses to MSO. This value has been shown 
to range approximately from 1 µM in E. coli to 1 mM in humans, with most reported values in the 
1-200 µM range(3). It takes approximately 8 moles each of MSO phosphate and ADP to achieve 
100% inhibition per mole of enzyme(1). MSO exists as four stereoisomers, but only the L,S 
configuration inhibits glutamine synthetase. The same diastereomer inhibits γ-glutamyl cysteine 
synthetase, in a similar ATP-driven fashion.  
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Figure 2. Methionine sulfoximine inhibits glutamine synthetase. Above: the reaction carried 
about by glutamine synthetase. Glutamate and ATP bind to the active site and ATP is hydrolyzed 
in the presence of magnesium and manganese ions to form gamma-glutamyl phosphate, a high-
energy intermediate, and ADP. The enzyme reacts NH3 with the intermediate to form glutamine, 
which is released from the enzyme along with inorganic phosphate. Below: the mechanism of 
glutamine synthetase inhibition by MSO. MSO competes with glutamate for binding to the active 
site. During the ATP hydrolysis step, the gamma phosphate of ATP is transferred to the imine 
nitrogen of MSO. The resulting molecule, MSO phosphate binds tightly to the enzyme and is not 
released, causing irreversible inhibition. 
 
ADP = adenosine diphosphate; ATP = adenosine triphosphate; Mg2+ = magnesium ion; 
Mn2+ = manganese ion; MSO = methionine sulfoximine; NH3 = ammonia; Pi = inorganic 
phosphate 
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The history of MSO 
MSO was first identified by Bentley et al in 1950 as a byproduct of the reaction that used 
trichloramine (NCl3), also called agene, to bleach flour(5). Throughout the previous decade, 
several investigators demonstrated that canines fed high levels of agenized flour exhibited running 
fits and convulsions, prompting a scientific pursuit of the “toxic factor” within the flour. Fearing 
that human consumption of agenized flour could potentially cause neurological diseases, such as 
epilepsy, the agene process was banned by regulatory agencies worldwide by l955, even though 
there was no evidence for toxicity in humans. The first ever publication describing the molecular 
structure of MSO labeled it as a “toxic factor” within the title, and shortly after its discovery and 
isolation, several investigators began to use MSO as a tool to study biochemical events leading to 
epileptic seizures. To test the effects of agenized flour on humans, Newell et al performed a study 
where a group of 19 children and adults consumed diets containing 22 to 30 times the amount of 
agenized protein in a normal American diet. The test population also included 5 epileptics. The 
diet was continued for up to 7 months, and no physical, neurological or electro-encephalographic 
changes were observed(5), refuting the belief that MSO was toxic. 
Although there is no evidence that MSO is toxic to humans: 1) the historical context in 
which MSO was discovered 2) the fact that early studies focused solely on MSO toxicity, and 3) its 
prevalent use as a tool to study epilepsy, have diminished interest within the scientific community 
to develop MSO as a therapeutic. However, aberrant glutamine synthetase activity is implicated in 
several neurological diseases, and MSO has been shown to effectively treat a variety of such 
conditions in experimental animal models.  In addition, since glutamine synthetase is essential for 
nitrogen metabolism and growth in Mycobacterium tuberculosis, and because MSO can inhibit all 
four isoforms of GS expressed by the pathogen, MSO has been described as a promising treatment 
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strategy for tuberculosis infection(6). Despite its ability to inhibit enzymes that affect levels of 
such important molecules, and despite, as will be described below, its activity in animal models of 
hepatic encephalopathy (HE), amyotrophic lateral sclerosis (ALS), and inflammation leading to 
liver failure, preconceived negative opinions of MSO pose a significant hurdle in developing this 
drug for human use.  
Glutamine synthetase triggers cerebral edema resulting from hyperammonemia 
Acute liver failure (ALF) can result from an inflammatory immune response to molecules 
found in various medications, bacteria, or viruses (e.g. hepatitis), from toxins, from an 
acetaminophen overdose, or from preexisting medical conditions. One of the most serious clinical 
consequences of ALF is overt HE, accompanied by cerebral edema.  Death of liver tissue results 
in hyperammonemia, which causes HE and leads to a dangerous elevation of intracranial 
pressure(7). HE severity is graded with the West Haven criteria, which are comprised of four 
grades, ranked by the severity of edema. Signs and symptoms of HE may be mild with little or no 
clinical signs of cerebral edema, as seen in patients with chronic liver disease (cirrhosis), or very 
severe with cerebral edema seen in overt HE resulting from ALF(8). 
A growing body of research has implicated elevated glutamine as central to the more 
serious forms of ALF and HE. Increases in blood and brain glutamine are increased in HE patients; 
it was shown in 1959 that cerebrospinal fluid glutamine levels correlate positively with the degree 
of HE severity(9). Post mortem analysis of HE patients revealed elevated levels of  brain 
glutamine(10), and proton magnetic resonance studies showed both HE and ALF patients 
displayed increased brain glutamine measurements that declined with clinical 
improvement(11,12).  Plasma ammonia traverses the blood brain barrier and increases the rate of 
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the glutamine synthetase reaction, due to the law of mass action. In brain, glutamine synthetase is 
located primarily within astrocytes, the site of pathology in HE patients(13,14).  
The Osmotic Gliopathy hypothesis 
Persistent arterial hyperammonemia is associated with increased micro dialysis 
measurements of brain glutamine(15). Considering the relationship between hyperammonemia 
and increased brain glutamine observed in HE patients, in 1986 Brusilow et al. proposed a 
biochemical basis of ammonia intoxication. The model, known as “osmotic gliopathy”, postulates 
that brain ammonia stimulates astrocyte glutamine synthesis activity, causing glutamine 
accumulation. Glutamine acts as an osmolyte, creating a hypertonic environment where the cell 
compensates by increasing influxes of water, causing cell swelling and brain edema(16). Osmotic 
stress and cell swelling caused by elevated glutamine not only impairs astrocyte function, but also 
compromises the functional integrity of glial, neuronal, and vascular units. 
The osmotic gliopathy hypothesis and the role of glutamine in the pathophysiology of  HE 
is supported by the observation that inhibiting astrocyte glutamine synthetase with methionine 
sulfoximine protected mice from ammonia toxicity(17). In this particular study, the LD50 of 
ammonia was 50% higher in the MSO treated mice than in controls. Interestingly, the peak brain 
concentration of ammonia in the MSO treated mice remained significantly higher than controls for 
up to 24 hours after the initial ammonium chloride injection, due to an increased base-line brain 
ammonia concentration from MSO pretreatment. Importantly, MSO protected 100% of the mice 
from death even though levels of both brain and blood ammonia remained higher than controls. In 
conclusion, ammonia intoxication does not depend merely on the presence of ammonia, but rather 
it is mediated by its major detoxification product, glutamine. This finding was corroborated in 
humans by a case study that showed encephalopathy was correlated with elevated brain glutamine 
9 
 
 
 
levels, but not with elevated ammonia levels(18). The results of this case study are shown in 
Figure 3. 
Figure 3. Evidence supporting osmotic gliopathy in a human patient. Results from a case study  
by Brusilow et al.(18) of a 22 year old female with acetaminophen induced liver failure. Coma 
score (based on the Glasgow coma scale) and the plasma concentrations of ammonia and glutamine 
are plotted against time after acetaminophen ingestion. Although ammonia levels return to normal, 
the patient remained comatose until plasma glutamine levels decreased, highlighting the 
relationship between hepatic encephalopathy and plasma glutamine concentration. 
MSO prevents hyperammonemic brain swelling by inhibiting glutamine synthetase 
MSO was shown to prevent astrocyte swelling and reduce cerebral edema in rats by 
reducing brain glutamine, although ammonia levels were elevated(19). Similar experiments have 
replicated the finding that MSO shows a protective effect against glutamine-mediated brain 
swelling. Blei et al. confirmed this effect in a liver failure model(20), while Hawkins et al. showed 
that MSO was able to prevent several metabolic symptoms of HE such as: the decrease in brain 
glucose consumption, the increase in blood-brain barrier permeability, and the increase in brain 
glutamine(21)  
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 It has also been proposed that glutamine produced during hyperammonemia is 
transported to the mitochondria, where is it is converted to glutamate, releasing ammonia(22). 
The ammonia released within the mitochondria stimulates NADPH oxidase activity, which 
generates reactive oxygen and nitrogen species (RONS). RONS activate p38 MAPK, which 
phosphorylates p53 on serine 392 and causes p53 accumulation within the nucleus, where it 
regulates the expression of several genes that promote cell cycle withdrawal. Senescence is 
believed to play a role in causing cognitive impairment in HE patients.  Astrocytes treated with 
ammonium chloride display several phenotypic hallmarks of p53 induced senescence, including 
decreased cell proliferation and DNA synthesis, and increased nuclear p53 accumulation and 
β-galactosidase expression(23).  Additionally, cultured rat astrocytes treated with ammonium 
chloride showed increased mRNA and protein expression of the Mrp4 transporter, which exports 
several molecules believed to contribute to the pathogenesis of HE(24). In both studies, MSO 
treatment completely abolished all deleterious effects of ammonia intoxication.  This “Trojan 
horse” hypothesis (25) also proposes that glutamine induces toxic effects leading to HE, but 
through a different mechanism than the osmotic gliopathy hypothesis. 
MSO as a treatment for excitotoxicity, stroke, and amyotrophic lateral sclerosis 
Several neurodegenerative diseases are believed to involve a component of glutamate 
excitotoxicity. Excitotoxicity refers to the overstimulation of  neuronal glutamate receptors, caused 
by excess background glutamate, leading to neuronal damage and cell death(26). Examples of 
these diseases include: Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis 
(ALS), Huntington’s disease, stroke, and Parkinson’s disease. During neurotransmission, 
glutamate is secreted into the synaptic cleft by the presynaptic neuron and binds to both ionotropic 
and metabotropic receptors on the surface of the post-synaptic neuron. Glutamatergic receptors 
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initiate downstream cell signaling events either through electrical (eg, ionotropic) or chemical 
(eg. metabotropic) mechanisms, both resulting in the accumulation of intracellular calcium. 
Normally, the level of extra-neuronal glutamate is kept very low to prevent overstimulation 
of these receptors, which leads to aberrant calcium signaling and apoptosis. To prevent the 
presence of excess glutamate within the synaptic cleft, the brain utilizes a glutamate-glutamine 
cycle, described in Figure 4. After neurotransmission, glutamate reuptake occurs rapidly through 
high-affinity transport proteins found in the membranes of surrounding astrocytes. Glutamate may 
be oxidized by mitochondrial metabolism or recycled as a neurotransmitter. Regarding the latter, 
glutamine synthetase converts glutamate into glutamine within the astrocyte(27). Glutamine, 
acting as an inactive precursor, can then be shuttled from the astrocyte to the presynaptic neuron, 
where glutaminase converts glutamine back into glutamate(28).  
Excitotoxicity is believed to involve some defect within this glutamate-glutamine cycle. 
Due to the cyclical nature of the glutamine synthetase and glutaminase reactions, and neuron 
dependence on astrocyte glutamine to supply glutamate, it has been shown that inhibiting brain 
glutamine synthetase leads to decreases in both glutamine and glutamate concentrations(29,30). 
Using MRI quantitation in different brain regions, Ghoddoussi et al. confirmed that MSO treatment 
reduces levels of both amino acids in a mouse model of ALS(31). 
Brain damage resulting from excitotoxicity is a prevalent aftereffect of stroke, created by 
the release of glutamate by damaged brain cells, as well as by the activity of glutaminase on 
glutamine released by these cells. In addition to hypoxic cell death that occurs at the site of the 
initial occlusion, extensive cell damage permeates throughout the area surrounding the ischemic 
core, known as the penumbra. The final volume of penumbra that is salvaged from injury is highly 
correlated with improved clinical outcomes(32). Swanson et al. showed that after middle cerebral 
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artery occlusion in rats, 52% of cortical gray matter, ipsilateral to the occlusion, became infarcted.  
Injecting MSO into the animals 24 hours prior to stroke decreased the mean infarct volume by 
33%, indicating the involvement of glutamine synthetase in the pathology of stroke, and that 
inhibiting the enzyme with MSO could provide a viable treatment.  
Figure 4. Brain glutamine/glutamate cycle. Blood glucose enters the brain and is metabolized 
via glycolysis or oxidative phosphorylation, where the latter produces α-KG. Through the reaction 
catalyzed by GDH, α-KG is conjugated with NH3 (not shown for clarity) to produce glutamate. 
GS expressed in astrocytes creates glutamine from glutamate and NH3, which is shuttled to the 
presynaptic neuron and reconverted back into glutamate and NH3 by GLS. Glutamate is packaged 
into synaptic vesicles and secreted into the synapse during neurotransmission. Glutamatergic 
receptors initiate downstream cell signaling pathways that lead to increases in intracellular Ca2+. 
Glutamate is taken up by high-affinity transport proteins in the astrocyte membrane, where it is 
either metabolized, or recycled. 
α-KG = alpha-ketoglutarate; Ca2+ = calcium ions; GDH = glutamate dehydrogenase; 
Glc = glucose; Gln = glutamine; GLS = glutaminase; Glu = glutamate; GS = glutamine synthetase; 
NH3 = ammonia. 
Excitotoxicity is also believed to play a significant role in the pathogenesis of ALS. Two 
inhibitors of glutamatergic neurotransmission, riluzole and gabapentin, were able to extend the 
lifespan the G93A superoxide dismutase 1 (SOD1) mouse model of a familial form of ALS(33). 
SOD1 exists within the cytosol and mitochondrial inner membrane space, catalyzing the 
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dismutation of superoxide to hydrogen peroxide and molecular oxygen. Our lab has demonstrated 
that MSO treatment extends the lifespan of the SOD1 G93A mouse up to 8%, and also restores the 
plasma amino acid signature observed in diseased animals towards the profile observed in wild-
type control animals(31,34). 
MSO as an anti-inflammatory for treating acute liver failure 
 Research in our lab has demonstrated that MSO can prevent death in a mouse model of 
acute liver failure(35). Injection of bacterial lipopolysaccharides (LPS) and D-galactosamine 
induces inflammatory liver failure and death by stimulating the uncontrolled release of pro-
inflammatory proteins by immune cells, a “cytokine storm.” When mice were pretreated with MSO 
at a dose 50 mg/kg, the overall survival of the mice increased from 20% to almost 80%. As will 
be described in subsequent chapters, this therapeutic effect is due to an anti-inflammatory 
mechanism of MSO on cells of innate immunity. MSO treatment resulted in decreased plasma and 
liver tissue levels of the major pro-inflammatory cytokines TNFα, IL-6, and IFNγ, among several 
other proteins. By reducing the plasma IL-6 concentration, MSO reduced activation of STAT3, a 
downstream transcription factor that controls inflammatory gene expression. MSO also prevented 
caspase 3 cleavage, which is involved in both extrinsic and intrinsic apoptosis. Therefore, MSO 
treatment reduces inflammation, prevents apoptosis, and affects several pathways involved in the 
immune response. The effects of MSO on immune cells is largely the focus of this manuscript, to 
be described in greater detail in the chapters to follow. 
Studies on MSO toxicity 
 As mentioned previously, the discovery of MSO emerged from canine studies, where these 
animals were shown to be extremely sensitive and displayed various psychomotor abnormalities 
after being exposed to the amino acid. In 1951, Gershoff and Elvehjem tested the toxicity of MSO 
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in several animal species, where it became apparent that MSO toxicity is species-specific. Rats 
were shown to tolerate an MSO dose of 150 mg/kg with no observed abnormalities, although 
convulsions were observed at higher doses. For non-human primates it was established that MSO 
is safe at doses ranging from 50-100 mg/kg. However, dogs exhibited toxic effects at MSO doses 
as low as 3-5 mg/kg(36).  
 Studies on glutamine synthetase enzymology from different species have concluded 
differences in kinetic characteristics. Mice can be selected for resistance to different dosages of 
MSO, and it has been demonstrated that MSO sensitivity is related to differences in the level of 
glutamine synthetase activity between strains(37). Additionally, administration of a well-tolerated 
MSO dose of 2.5 mg/kg to non-human primates produced the same degree of inhibition of brain 
glutamine synthetase as 100 mg/kg produced in rats(7). Lastly mice injected with 20 mg/kg MSO, 
three times per week for 10 weeks, showed no signs of impairment of cognition and very minimal 
side effects, even though this dose inhibited brain glutamine synthetase by 80% compared to 
control mice(38). In summary, animal studies have concluded that MSO sensitivity is species-
specific, suggest that MSO can be tolerated for extended periods of time, and provide evidence 
that MSO may be safer and more effective in primates. 
 The only human study of MSO was performed in 1961 by Krakoff in seven patients with 
terminal cancer(39). Patients were given a variety of uncharacterized dosages of MSO over periods 
of time ranging from 2 to 8 days, with no description of the purity and exact composition of the 
MSO preparations. There is no way of knowing exactly what compounds those patients were being 
injected with. The enzymology of MSO was not available at the time, and the dosing schedule 
described in the narrative was inappropriate for a long-lasting inhibitor. Four patients described 
having hallucinations which subsided after treatment was discontinued, but no serious adverse 
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events were reported. Therefore, no data exist indicating MSO is toxic to humans, and available 
data suggest that primate glutamine synthetase is inhibited at doses that are not neurotoxic and do 
not produce convulsions. Table 1 summarizes the various toxicity studies on MSO and lists the 
doses of MSO discovered to be toxic or tolerable for each species. 
Author Dog Rat Mouse Rabbit Cat Primate 
Bentley(40) 2.0 
  
2.0 
  
Gershoff(36) 3.0 (150) 
   
100b 
Krakoff(39) 
     
(0.2-8)c 
Proler(41) 
    
18-20 
 
Warren(17) 
  
(50) 
   
Wada(42) 
 
(100) 
  
7.5 
 
Apostolakis(43) 
   
3-9a 
  
Blin(38) 
  
(chronic)d 
   
Brusilow(7) 
     
(2.5)b 
Table 1. MSO toxicity is species-specific. This table lists the authors of studies on 
MSO toxicity versus the species tested, and the doses of MSO (mg/kg) that 
were shown to be toxic or tolerated (in parentheses) by each of the tested 
species in each study. 
a: Developed spastic diplegia 
b: Non-human primate 
c: In humans – varying doses, estimates assuming 50 kg body weight  
d: Ten weeks of MSO: 20 mg/kg, 3 times/week  
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CHAPTER 2 
Macrophage physiology in innate immunity and inflammation 
PART 1: Macrophages are a major component of innate immune response to infection 
Macrophages  
Macrophages are specialized white blood cells that detect and eliminate dangerous 
pathogens and remove other undesirable particles from the blood and tissues. Macrophages are the 
largest of the leukocytes, ranging in size from 20-30 microns in diameter. Originally described by 
Nobel Laureate Élie Metchnikoff in 1882, macrophages are often referred to non-specifically as 
phagocytes, a translation of Greek origin meaning “devouring cell” which reflects their ability to 
engulf microorganisms in a process known as phagocytosis. Macrophage populations are found in 
essentially every tissue of the body, comprising heterogeneous sub-populations that have niche-
specific functions. Table 2 highlights distinct macrophage populations known as the tissue-
resident macrophages.  
It was originally thought that all macrophages originate from the bone marrow, as 
hematopoietic stem cells (HSCs), and proceed to differentiate into myeloid precursors of 
increasingly committed cellular fates before reaching a terminal point of differentiation as 
immature leukocytes of the plasma known as monocytes. After receiving an environmental 
stimulus, monocytes are attracted towards the site of a local infection, extravasate from the blood 
vessels into tissues, and mature into inflammatory macrophages and myeloid lineage dendritic 
cells. However, recent data from lineage tracing and fate-mapping experiments support a prenatal 
origin of tissue-resident macrophages, which have been shown to maintain local populations 
through self-renewal, with very little contribution in number from blood-derived monocyte 
precursors(44). Albeit the enormous genetic and functional complexity being unearthed in recent 
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years, in the context of innate immunity all macrophage populations share the common features of 
initiating, maintaining, and resolving inflammatory responses to infection. 
In addition to orchestrating the inflammatory response, macrophages aid in homeostatic 
processes such as wound healing, tissue regeneration, and tissue homeostasis. Tissue injury 
involves multiple phases and macrophages have been shown to be essential mediators during each 
phase. Injury such as a traumatic insult results in necrotic cell death and the release of damage-
associated molecular patterns (DAMPS) that act as endogenous danger signals. Highly 
characterized DAMPS include serum amyloid A, high mobility group box-1, calgranulin A and B, 
and ATP(45). DAMPS bind to extracellular receptors on macrophages and act to induce, amplify, 
or perpetuate inflammatory responses. 
During the inflammatory phase of injury, macrophages regulate inflammation, clear 
apoptotic cell debris, and promote epithelial cell proliferation(46). During the formation of new 
tissue, macrophages are a major source of growth factors essential for cell proliferation, 
differentiation, and the generation of extracellular matrix. Macrophage depleted mice show 
impaired angiogenesis, decreased cell proliferation, and a delay in cell repopulation at the wound 
site after injury(47). Macrophages also resolve inflammatory responses during wound healing by 
secreting anti-inflammatory cytokines and ingesting apoptotic neutrophils. Macrophages increase 
arginase expression, which converts arginine to ornithine. Ornithine is used to synthesize hydroxy-
proline and polyamines, which are essential for extracellular matrix formation and cell 
proliferation, respectively. Lastly, during tissue remodeling, a dynamic process that involves the 
reorganization of wounded tissue, macrophages remove cell debris and excess extracellular matrix 
fragments around the wound. 
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Table 2. Location and function of distinct macrophage subpopulations. Tissue resident 
macrophages arise from distinct lineages and perform tissue-specific functions. 
Macrophages initiate the immune response to infection 
 Macrophages fall under a broad classification of immune cells known as antigen presenting 
cells (APCs) which specialize in the recognition, processing, and presentation of non-self antigens 
to cells of the adaptive immune system known as T-lymphocytes. It is through the process of 
antigen presentation that an acquired, or “adaptive” immune response can be generated against a 
specific epitope. Although almost all cell types can exhibit some form of antigen presentation, 
macrophages, along with dendritic cells and B-lymphocytes express MHC class II receptors, 
pattern recognition receptors, and co-stimulatory molecules that make them especially proficient 
for the task, and as such these cells are sometimes referred to as “professional APCs.” Following 
this distinction, macrophages are biological sentinels that serve as a first line of defense in 
recognizing both intracellular and extracellular pathogens. 
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 As innate immune cells, macrophages have evolved to possess receptors that recognize 
conserved structural elements contained in several bacterial and viral species known as pathogen-
associated molecular patterns (PAMPS). Several PAMPS have been identified and the germline-
encoded receptors that recognize these motifs are known as pattern recognition receptors (PRRs). 
The binding of a PAMP to its cognate PRR leads to activation of the receptor, and information is 
transmitted from the plasma membrane to the nucleus through an array of cell-signaling pathways. 
These pathways usually overlap, and converge in the activation of one or more major transcription 
factors, such as NF-κB and the MAP kinases, which bind to promoter regions and activate the 
transcription of genes involved in pro-inflammatory and anti-microbial responses(48). Broadly, 
pattern recognition receptors can be divided into two classes based on the types of pathogens they 
recognize: extracellular PRRs and intracellular PRRs. The most widely studied intracellular and 
extracellular PRR families are the NOD-like receptors, and the Toll-like receptors, respectively.  
NOD-like receptors 
The nucleotide oligomerization domain (Nod)-like receptors (NLRs), are cytosolic pattern 
recognition receptors that are involved mainly in the recognition of bacteria that have entered the 
cell via infection or phagocytosis. There are 23 NLR members found in humans, which are 
expressed in immune tissue and epithelial cells, but the expression of certain NLRs is restricted to 
phagocytes(49). The most widely studied NLRs are NOD1 and NOD2, which recognize distinct 
structural motifs within peptidoglycan, a major cell wall constituent found in almost all bacteria. 
NOD1 and NOD2 contain 1) an N-terminal caspase recruitment (CARD) domain involved in 
downstream cell signaling and effector functions, 2) a nucleotide oligomerization domain that is 
critical for activation, and 3) a leucine-rich repeat containing C-terminal domain which recognizes 
peptidoglycan. Proper NLR function is critical for priming rapid innate immune responses, and 
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NLR signaling initiated inside of the cell can exhibit cross-talk with other innate receptors(50).  In 
addition, NOD1-/- mice were shown to be more susceptible than wild-type mice to early 
pneumococcal sepsis(51). NLR signaling has also been shown to play a role in development and 
apoptosis, and abnormal NLR signaling is associated with increased susceptibility to an array of 
inflammatory diseases such Crohn’s disease, gout, and cancer(52). 
Toll-like receptors 
Toll-like receptors (TLRs) are pattern recognition receptors expressed within the plasma 
membranes of immune cells, epithelial cells, endothelial cells, and fibroblasts, and serve to 
recognize extracellular PAMPS. The Toll gene was first described in D. melanogaster as an 
important regulator of dorsoventral polarity during larvae development(53), as well being essential 
for antifungal responses(54). The toll-like receptor family includes 10 members in humans, and 
three additional members in mice. Table 3 describes human members of the TLR family and 
cognate ligands.  TLR activation leads to the recruitment of adapter proteins and the activation of 
protein kinases that phosphorylate transcription factors that promote the expression of genes 
involved in pro-inflammatory and anti-microbial processes. Such antigen-induced processes 
include the promotion of cell proliferation, the expression of pro-inflammatory mediators known 
as cytokines, and increased survival. Cytokines produced through TLR signaling orchestrate the 
immune response to infection, binding to receptors on various target tissues and enhancing both 
innate and adaptive immune cell functions. Cytokine signaling is discussed in greater detail 
towards the end of Part 1 of this chapter. 
In addition, the binding of bacterial constituents to TLRs mediates phagocytosis, where 
microbes are ingested, destroyed, and peptide antigens are packaged into MHC class II molecules, 
and presented to cells of adaptive immunity. Therefore, TLR signaling produces a link between 
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innate functions and the development of an acquired immune response. Several mutations in 
various members of the TLR family have been described in humans and have been linked to 
increased susceptibility of developing various inflammatory diseases(55).  
 
Table 3. Human Toll-like receptors and cognate ligands. Toll-like receptors present on cells 
of innate immunity recognize a variety of pathogen associated molecular patterns. 
Toll-like receptor 4 recognizes lipopolysaccharide 
A critical advancement of contemporary understanding of innate immunity occurred in 
1998, when Nobel Laureate, Bruce Beutler and colleagues discovered that lipopolysaccharide 
(LPS), the major constituent of the outer membrane of gram-negative bacteria, is recognized by 
Toll-like receptor family member 4 (TLR-4), and that mice with mutations in TLR-4 were 
unable to generate an immune response to LPS(56). LPS is a PAMP that induces systemic 
inflammation and septic shock in animal models when administered in excessive doses. The 
work of Beutler’s group triggered an explosion of research in the field of TLR signaling, and as a 
result the LPS-induced TLR-4 signaling pathway has been characterized to appreciable detail. 
Figure 5 provides a schematic of one arm of the highly complex TLR-4 signaling pathway 
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involved in the expression of pro-inflammatory cytokines, known as the MyD88 dependent 
pathway. 
TLR-4 signaling begins with the recruitment of LPS to the receptor binding site. This is 
facilitated by a series of proteins including lipopolysaccharide binding protein (LBP), CD14, 
myeloid differentiation factor 2 (MD-2) and TLR-4. LBP is a soluble protein found in the plasma 
that binds to LPS and complexes with CD14. CD14, a glycophosphatidylinositol-linked membrane 
protein, directs the transfer of LPS to the TLR-4 receptor. TLR-4 cannot recognize LPS alone and 
therefore it is a requirement for signaling that the receptor non-covalently interacts with MD-2. 
Upon the formation of the LPS binding complex, monomers of the TLR-4 complex oligomerize, 
and the receptor assumes an activated conformation, exposing a toll/interleukin-1 receptor (TIR) 
domain on the cytoplasmic face of the membrane which recruits TIR-domain containing adapter 
proteins. Five TIR-domain containing proteins that interact with TLR-4 have been identified, but 
only two of them are involved in the pathway that leads to gene expression of pro-inflammatory 
cytokines. This signaling pathway is known as the myeloid differentiation primary response gene 
88 (MyD88) dependent pathway, and the adapter proteins that facilitate this pathway are MyD88, 
and TIR domain-containing adaptor protein (TIRAP)(57). 
After activation of the receptor, TIRAP associates with the cytoplasmic tail of TLR-4 
through TIR domain interactions. TIRAP then recruits MyD88, which also binds to TLR-4 and 
initiates MyD88 dependent signaling. MyD88 contains a death domain (DD) which recruits a DD-
containing kinase known as IL-1 receptor-associated kinase-4 (IRAK-4). IRAK-4 becomes 
activated through this interaction and from here a series of kinase mediated signaling events occur. 
IRAK-4 activates IRAK-1, which phosphorylates another adapter protein known as TNF receptor-
associated factor 6 (TRAF6). TRAF6 associates with two ubiquitin conjugating enzymes and 
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collectively this protein complex activates transforming growth factor-b-activated kinase (TAK1). 
TAK1 kinase activates the mitogen activated protein kinases (MAPK) as well as IκB kinase (IKK). 
 IKK phosphorylates IκB, an inhibitor bound to the transcription factor NFκB that regulates 
the expression of pro-inflammatory cytokines, genes involved in antigen presentation, 
immunoreceptors, adhesion molecules, and other miscellaneous genes involved in the immune 
response. Phosphorylated IκB dissociates from NFκB and is marked for proteasomal degradation, 
leaving the free form of NFκB which transports to the nucleus and activates transcription. An 
additional transcription factor that is involved in the gene expression of pro-inflammatory 
cytokines, AP-1 is also phosphorylated through MAPK signaling.  
Figure 5. Rudimentary outline of the MyD88-dependent TLR-4 signaling pathway. 
Macrophage mediated maintenance of immune responses 
 Macrophages initiate the immune response to infection through receptor-antigen 
interactions. Upon activation, macrophages provide critical support functions necessary to 
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establish a local, non-adaptive immune response, but as mentioned earlier they also present 
antigens to adaptive immune cells and secrete factors that influence the functional differentiation 
of these cells. Broadly, macrophages have three major effector functions during the generation and 
maintenance of an inflammatory response. These functions are 1) phagocytosis, 2) antigen 
presentation, and 3) immunomodulation. 
Phagocytosis 
Phagocytosis describes the process by which phagocytes including macrophages, dendritic 
cells, and neutrophils engulf microbes and absorb them into the cell. Phagocytosis occurs after 
specific antigens are recognized by phagocytic receptors on the cell surface, where after the cell 
forms membranous protrusions that surround the microbe and draw it into the cell, forming 
vesicular structures known as phagosomes. Phagocytosis is the first step of the trapping and killing 
of microbes within infected tissue and is also necessary for providing the cell with antigenic 
molecules to be packaged and presented to T-lymphocytes on the cell surface, as the first step of 
generating an acquired immune response. Macrophages possess an array of phagocytic receptors 
that can be classified based on ligand specificity(58). Table 4 highlights some of the more 
characterized phagocytic receptors and their ligands.  
Once absorbed into the cell, microbes within the phagosome are immediately exposed to 
reactive oxygen species generated by NADPH oxidase, which reduces atmospheric oxygen to 
superoxide (O2
-)(59). The phagosome fuses with the lysosome to form a structure known as the 
phagolysosome. Proton ATPases within the membrane of the phagolysosome lower the pH and 
this acidification, along with the action of glycosidases and proteases within the phagolysosome 
forms an effective sterilization system (60). 
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Table 4. Macrophage phagocytic receptors and their ligands. 
Antigen Presentation 
Antigen presentation is a complex process by which APC’s such as macrophages, dendritic 
cells, and B lymphocytes present antigens to T lymphocytes in the form of short peptide fragments. 
Microbes internalized through phagocytosis are degraded and their proteins are digested into short 
peptide chains by acidic proteases such as cathepsins B, D, and L(61). The processed peptides 
generated from extracellular pathogens are packaged into receptors known as major 
histocompatibility complex, class II (MHC class II). To fully appreciate the complexity of antigen 
presentation, it is essential to possess a fundamental understanding of the MHC system, which is 
the vehicle the human body uses to distinguish between self and non-self antigens. 
The major histocompatibility complex (MHC) is a large polygenic locus of 4 million base 
pairs that contains at least 50 genes. In addition, the MHC genes are the most polymorphic genes 
known, with each gene having multiple alleles. In humans the MHC is referred to as the human 
leukocyte antigen system (HLA). HLA genes are divided into two classes, each with 3 pairs of 
genes which are expressed differentially on cells. MHC class I molecules present antigens from 
the cytosol whereas MHC class II molecules present extracellular derived antigens. Macrophages 
and B lymphocytes express MHC class II molecules, which are loaded with antigenic peptides and 
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displayed to a class of T lymphocytes known as T-helper cells. The T cell receptor on these cells 
recognizes the antigen within the MHC class II receptor, and through this interaction and other 
costimulatory mechanisms the T helper cells become activated. The main function of T helper 
cells is to activate other cells of the immune system, including B lymphocytes which are stimulated 
to secrete antibodies against the antigen recognized by the T cell. In summary, the generation of 
an acquired immune response depends on antigen presentation by macrophages. 
Immunomodulation 
In addition to performing the processes of phagocytosis and antigen presentation, 
macrophages contribute significantly to the inflammatory response by changing the functions of 
other cells. By influencing the activities of other cells, macrophages globally regulate immune 
responses. The process of increasing or decreasing the activity of the immune system is referred 
to as immunomodulation. Activated macrophages influence the immune response 1) directly, by 
forming cell-cell contacts facilitated by receptor/ligand interactions and 2) indirectly, by secreting 
various agents that act upon cells of the immune system. By secreting these various factors, 
macrophages provide cells with a molecular language and a system of communication that spans 
the level of the entire organism.  
Immunomodulatory agents secreted by macrophages include cytokines, chemokines, 
bradykinins, leukotrienes, and prostaglandins. Importantly, immunomodulation by macrophages 
can either suppress, or promote the inflammatory response, and such processes are tightly 
controlled under normal circumstance. Likewise, defects in macrophage-mediated 
immunomodulation are linked to human disease, largely through an excessive production of the 
pro-inflammatory signaling proteins known as cytokines. 
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Pro-inflammatory Cytokines 
In response to antigen, activated macrophages provide a first line of defense by secreting a 
variety of factors that orchestrate inflammation and direct the development of the humoral immune 
response. These factors, known as cytokines, are a class of soluble, or membrane-bound messenger 
proteins involved in autocrine, paracrine, and endocrine signaling networks(62). Cytokines bind 
to receptors on a variety of target tissues, exerting pleiotropic effects that influence cell to cell 
communication, functional maturation, and cell behavior. More than 200 cytokines have been 
identified and these proteins are grouped broadly as being either pro-inflammatory or anti-
inflammatory. Cytokines are further divided into subgroups that share similar biological functions. 
These include the interleukins, growth factors, chemokines, interferons, and hematopoietic 
factors(63).  
Many cytokines have redundant or overlapping functions, acting in concert to regulate 
several homeostatic processes such as growth and development, wound healing, cell division, 
chemotaxis, lymphocyte maturation, and inflammation collectively(64). An imbalance between 
pro-inflammatory and anti-inflammatory functions mediated by cytokines is observed in several 
human diseases(65). Macrophages are capable of producing large quantities of several pro-
inflammatory cytokines, and excessive levels of these proteins in circulation can progress the 
development of acute and chronic inflammatory syndromes. The best studied pro-inflammatory 
cytokines produced by macrophages, and perhaps the most clinically relevant, include: Tumor 
necrosis factor alpha (TNFα), Interleukin 6 (IL-6), Interleukin 1 beta (IL-1β), and Interleukin 12 
(IL-12).  
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 Tumor Necrosis Factor Alpha (TNFα) 
TNFα is a pro-inflammatory cytokine produced predominantly by activated macrophages 
and acts as a key regulator of the immune response and is therefore one of the most clinically 
relevant and actively investigated cytokines. Those investigations have dissected both distinct and 
overlapping signal transduction pathways mediated through TNFα, which influence a range of 
cellular functions including cell death, survival, differentiation, migration, and proliferation(66). 
Excessive TNFα production is a consequence of several diseases including auto-immune and 
chronic inflammatory syndromes. TNFα acts specifically on endothelial cells, stimulating the 
upregulation of cell-surface adhesion proteins that bind to neutrophils and facilitate cell migration 
from blood into tissue during local infection(67). Additionally, morphological changes are 
exhibited by endothelial cells upon interaction with TNFα, such as the disruption of adherens 
junctions resulting in increased vascular permeability(68,69). Four monoclonal anti-TNFα 
antibodies and one recombinant TNFα receptor fusion protein have been approved by the FDA to 
treat rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease(66).  
TNFα acts directly and in concert with other cytokines and chemokines to increase 
neutrophil phagocytosis and respiratory burst capacity used by these to cells capture and eliminate 
pathogens(70,71). Furthermore, TNFα, along with IL-6 and IL-1β, stimulate hepatocytes to 
produce acute phase response proteins, constituting yet another critical arm of the innate immune 
response. TNFα acts in both an autocrine and paracrine fashion, binding to cell surface receptors 
on macrophages to initiate its own synthesis(72). In this manner an abundance of TNFα is 
produced and in severe cases of atypical immune responses TNFα can travel systemically through 
circulation, acting in a hormonal fashion on distal organs. TNFα has been confirmed as the 
principal mediator of lethality from E. coli endotoxin, evidenced by the fact that baboons passively 
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immunized with a neutralizing anti-TNFα antibody and subsequently infused with a lethal dose of 
live E. coli are protected against shock, vital organ failure and death(73).  Insofar as clinical 
relevance, adalimumab, a monoclonal antibody to TNFα marketed under the tradename Humira®, 
is widely advertised as a treatment for arthritis, psoriasis, Crohn’s syndrome, and other 
inflammatory disorders, generating approximately $16B/year in sales. 
Interleukin 6 (IL-6) 
IL-6 is a keystone cytokine, exerting both pro-inflammatory and anti-inflammatory effects 
on a diverse range of cell types depending on its mode of signaling(74). Perhaps the most 
significant pro-inflammatory role of IL-6 is triggering the acute phase response. Castell et. al 
concluded that IL-6 controls the acute phase response in human liver cells through demonstration 
that IL-6 was both necessary and sufficient to induce the full spectrum of acute phase response 
proteins. In primary human hepatocytes, recombinant human IL-6 was capable of inducing C-
reactive protein, serum amyloid A, alpha 1-antichymotrypsin, and fibrinogen synthesis in a dose 
and time dependent manner. Also, a significant decrease in fibronectin, albumin, and transferrin 
was observed compared to controls(75). Plasma IL-6 concentration increases 10-100 fold during 
infection and it has been proposed that IL-6 could be used as a highly accurate diagnostic marker 
of sepsis(76). 
Additionally, IL-6 has a principal role in bridging innate and adaptive immunity during 
prolonged infection. IL-6 was initially discovered as a factor secreted by T cells that stimulated 
activated B cells to differentiate into antibody secreting plasma cells without stimulating B cell 
proliferation(77,78). IL-6 was also characterized as a B cell stimulating growth factor in B cell 
hybridoma cell lines. IL-6 has been shown to be necessary for T lymphocyte recruitment(79) and 
rescues these cells from entering apoptosis(80). The overproduction of IL-6 is implicated in the 
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pathology of inflammatory and auto-immune disorders including rheumatoid arthritis, where IL-6 
is over-expressed in synovial tissue. Tocilizumab, a humanized anti-human IL-6 receptor antibody 
has been approved by the FDA to treat rheumatoid arthritis and is also a primary treatment for life-
threatening inflammatory immune response that sometimes occurs in anti-cancer immunotherapy. 
Interleukin 1 Beta (IL-1β) 
IL-1β is one of seven pro-inflammatory cytokines of the interleukin 1 family. IL-1β 
secreted by macrophages establishes an axis between the immune and neuro-endocrine systems. 
IL-1β stimulates the hypothalamus to increase gene expression of cyclooxygenase-2 (COX-2), 
which plays a key role in the synthesis of prostaglandin E2 (PGE2). PGE2 is an endogenous 
pyrogen that induces fever, vasodilation, and pain hypersensitivity. Patients injected with IL-1 
experience fever, headache, and pain in muscles and joints, all mediated through COX-2 
activity(81). In many scenarios IL-1β synergizes with TNFα, mediating the adhesion of  
neutrophils to the surface of the endothelium, and inducing nitric oxide production(63). The 
significance of IL-1β in mediating the inflammatory response is highlighted by the fact that 
mutations in genes that regulate the production of IL-1β cause Cryopyrin-associated periodic 
syndrome (CAPS), a group of systemic autoinflammatory syndromes(82). 
Interleukin 12 (IL-12)  
IL-12 is an integral cytokine that brings innate and adaptive immune responses together. 
This is achieved by the ability of IL-12 to induce functional maturation of T lymphocytes(83). 
Specifically, IL-12 secreted by activated macrophages provides a co-stimulatory signal that directs 
the development of the Th1 subset of T-helper cells. Th1 effector cells initiate host defense against 
bacteria and protozoa as major producers of interferon gamma (IFNγ), a cytokine that enhances 
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antimicrobial functions of neutrophils and macrophages. Additionally, IL-12 stimulates the 
proliferation of T cells and natural killer cells, and enhances cytolytic functions of these cells(84). 
Chemokines  
During the immune response, leukocytes are recruited from various regions of the body to 
the site of a local infection. Cell migration is accomplished through a system based on chemical 
attraction, known as chemotaxis. Activated macrophages secrete several chemoattractant proteins 
called chemokines into the blood which are recognized by chemoreceptors on neutrophils, natural 
killer cells, and T lymphocytes. Chemoreceptors are embedded uniformly within the plasma 
membrane of immune cells, which permits the recognition of chemical concentration gradients 
and subsequent migration towards the source of the chemokine. 
Chemokines have been classified into four subfamilies based on the relative position of 
cysteine residues (CXC, CC, C and CX3C)(85). In addition to inducing cell motility, chemokines 
also affect angiogenesis and cell proliferation. Certain chemokines are secreted constitutively to 
promote basal leukocyte migration, whereas others are only synthesized during inflammatory 
conditions. Pro-inflammatory chemokines secreted by macrophages include CCL2, CCL3, CCL5, 
CXCL1, CXCL2 and CXCL8. In addition to chemokines, macrophages secrete other chemotactic 
small molecules, including prostaglandin D2, leukotrienes, and other eicosanoid lipid mediators. 
32 
 
 
 
Macrophages resolve inflammatory responses 
As immunomodulating cells, macrophages mediate the direction and the duration of the 
immune response to infection. Inflammation is a taxing stress response that requires significant 
metabolic resources, and prolonged bouts of inflammation generally causes damage to healthy 
tissue. Therefore, macrophages possess tightly controlled mechanisms to control the 
spatiotemporal sequence of initiation, maintenance, and resolution of the immune response. 
Defects in molecular switches that regulate macrophage responses can have severe acute 
consequences, and if these situations become chronic, may lead to inflammatory disease.  
Macrophage activation is controlled through metabolic shifts, and impinging upon 
metabolic signaling pathways impacts the function of these cells. Nutrient deprivation starves 
immune cells of ATP and activates AMP-activated protein kinase (AMPK) signaling, which 
suppresses several anabolic pathways(86). Additionally, various metabolites and vitamins have 
been discovered to promote anti-inflammatory genetic programs in isolated macrophages. In 
mouse peritoneal macrophages, vitamin A was shown to activate the transcription factor GATA6, 
which promotes the expression of anti-inflammatory genes(87). Macrophages produce the major 
anti-inflammatory cytokine, interleukin 10 (IL-10) which activates AMPK signaling and turns off 
the expression of the pro-inflammatory cytokines.  
The destructive potential of uncontrolled macrophage activation is also prevented through 
a type of activation induced cell death (AICD) that is developmentally regulated. In human 
monocyte cultures, it was discovered that cells exposed to macrophage colony-stimulating factor, 
a maturation promoting cytokine, displayed decreased sensitivity to AICD. However, IFNγ-
primed cells showed increased sensitivity to AICD. IFNγ-primed monocytes that were 
33 
 
 
 
differentiated into activated macrophages in vitro retained this sensitivity to AICD, showing that 
macrophage AICD is developmentally regulated by cytokines(88). 
PART II: Macrophage polarization states in the context of inflammatory disease 
Macrophage Polarization Model 
As biological sentinels, macrophages constantly survey the surrounding environment and 
receive combinations of sensory input from a variety of stimuli. In addition, macrophages are 
dynamic, participating in diverse homeostatic processes. Therefore, diversity and plasticity are 
functional hallmarks of macrophages; these cells can assume a spectrum of activation states 
contextual to the microenvironment(89). Research on the mechanisms of bacterial killing by 
macrophages gradually led to the development of a model that accounts for macrophage 
heterogeneity and functional plasticity, known as macrophage polarization.  
Background 
It was well established by the 1960’s that diversity in structure and function existed 
between classes of immunoglobulins secreted by B lymphocytes, and a system was put in place to 
characterize the basic proteins of the antibody response(90). However, it remained unclear how 
distinct effector functions mediated by antibodies were coupled with cell mediated immunity. In 
1986 a dichotomy of T lymphocyte subclasses was hypothesized by Mossman and Coffman, who 
proposed that these 2 populations of cells, termed Th1 and Th2, could be characterized by which 
cytokines they secrete(91). The Th1 subset produce high levels of IFNγ and are involved in pro-
inflammatory processes, whereas the Th2 subset produces IL-4 and IL-13 and promotes allergic 
responses.  
Data supporting heterogeneity within T helper cell functions already existed at that time, 
with additional evidence to come. In 1983 it was revealed that IFNγ secreted by T lymphocytes 
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caused resting macrophages to transform into active cells with enhanced antimicrobial 
capacities(92). This finding identified IFNγ as the first molecule to induce “classical activation”, 
a term introduced 20 years prior by Mackaness who noted an enhanced but non-specific 
inflammatory response by macrophages upon re-exposure to pathogen(93). In 1990 it was 
discovered that macrophages incubated with IL-4 assumed an activated state that differed from 
cells activated with IFNγ (94). Hence the term “alternative activation” was subsequently coined to 
describe macrophages stimulated with IL-4. 
M1/M2 Macrophage Paradigm 
Echoing the classification system created for characterizing T helper cell subsets, a similar 
concept was originally proposed for macrophages. The proinflammatory phenotype assumed by 
classically activated macrophages was coined “M1.” Along with IFNγ, LPS and TNFα can also 
induce the M1 phenotype. These cells express pro-inflammatory cytokines, exhibit enhanced 
production of reactive oxygen and nitrogen species, and have strong anti-microbial and anti-tumor 
activity. The alternatively activated macrophage was initially referred to as M2. Compared to M1 
cells, M2 cells have upregulated MHC-II and mannose receptor expression and decreased 
respiratory burst capacity. IL-4 and IL-13 can induce the M2 state, and these cells function in 
parasite infection, tissue remodeling, and tumor progression. The M2 state has been expanded into 
four groups, M2a-d, that differ by the induction stimulus, surface/expression markers, and secreted 
factors. 
Despite providing a useful framework for understanding select in vitro responses to 
independent stimuli, the M1/M2 model does not accurately reflect macrophage biology, does not 
account for heterogeneity among macrophage subpopulations, and lacks comprehensiveness. The 
M1 and M2 signatures do not always exclude one another and often overlap. Expression markers 
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traditionally used to distinguish M1 from M2 macrophages are lacking. Furthermore, stimulatory 
signals received by macrophages are dynamic, pleiotropic, and coexisting in vivo. Expanding upon 
this, the M1/M2 paradigm neglects to consider that these inputs have combinatory, concentration-
dependent effects, have diverse actions at different stages of cell development, and often integrate 
intracellular signaling pathways that implement novel genetic programs. In vivo, macrophages are 
exposed to combinations and concentrations of cytokines, chemokines, adhesion molecules, cells, 
and other factors. Therefore, contemporary literature has called for the reassessment of the 
traditional bipolar model of macrophage polarization(94). 
The current, favored view of macrophage polarization involves a spectrum of activation 
states with M1 and M2 serving as poles(95). Functional skewing of macrophage polarization states 
has been shown to occur under normal conditions, as well as during pathology. The biomedical 
impact of this hypothesis of heterogenous activation states is that macrophages could potentially 
be swayed from phenotypes that contribute to disease and attracted toward a more favorable state 
through macrophage-centered therapies(89). 
Macrophage polarization in inflammatory disease 
Acute Liver Failure 
Acute liver failure (ALF) is defined as a loss of liver function that occurs rapidly in patients 
who usually have no history of liver disease. ALF is  relatively rare, but shares a commonality 
with several more prevalent diseases in that its cause and progression involves severe, systemic 
inflammation. 20 percent of the non-parenchymal mass of liver is composed of resident 
macrophages known as Kupffer cells. ALF develops when Kupffer cells become polarized towards 
a pro-inflammatory state and secrete a bolus of proinflammatory cytokines into systemic 
circulation, creating what is referred to in the clinic as a “cytokine storm”. 
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Kupffer cells secrete TNF-α, IL-6 and IL-1 which promotes the synthesis and secretion of 
acute phase proteins by hepatocytes. These proteins include C-reactive protein and mannose 
binding lecithin, which function similarly to antibodies but lack specificity. The combined 
actions of acute phase proteins and cytokines trigger tissue injury, exacerbating the inflammatory 
response further. Hepatocyte cell death pathways are activated, leading to metabolic 
complications, coagulopathy, brain swelling, and potentially death. Since ALF can be initiated 
and progressed by macrophage mediated inflammation, skewing macrophage polarization from 
pro-inflammatory to anti-inflammatory would provide a viable treatment option for patients that 
currently have few available options.  
COPD and Asthma. 
COPD and asthma are major global health problems, with COPD predicted to become the 
third largest cause of death globally by 2020(96), and asthma remains widespread in both 
developed and developing countries. Chronic, low grade inflammation of the lungs contributes 
substantially to the pathogenesis of COPD and asthma. In COPD, chronic activation of innate 
immune cells and increased leukocyte migration leads to airway remodeling and thickening which 
can lead to irreversible damage(97,98). Alveolar macrophages (AMs) comprise 90 percent of the 
pulmonary macrophage population and are implicated in the progression of COPD and asthma(99). 
These resident macrophages are constantly exposed to inhaled substances, functioning as the first 
line of host defense against inhaled irritants. Clinical research implicates that macrophages are 
inappropriately activated during the development of these disorders. 
  
37 
 
 
 
CHAPTER 3 
In vitro suppression of inflammatory cytokine response by methionine sulfoximine. 
The work presented here is an expansion of recently published work: 
Peters TJ, Jambekar AA, Brusilow WSAB. In vitro suppression of inflammatory cytokine response 
by methionine sulfoximine. (2018). The Journal of Inflammation. 
Abstract 
The glutamine synthetase inhibitor methionine sulfoximine (MSO), shown previously to 
prevent death caused by an inflammatory liver response in mice, was tested on in vitro production 
of cytokines by mouse peritoneal macrophages triggered with lipopolysaccharide (LPS).  
MSO significantly reduced the production of Interleukin 6 (IL-6) and Tumor Necrosis Factor 
Alpha (TNFα) at 4 and 6 hours after LPS-treatment.  This reduction did not result from decreased 
transcription of IL-6 and TNFα genes, and therefore appeared to result from post-transcriptional 
inhibition of synthesis of these cytokines.  MSO treatment did not inhibit total protein synthesis 
and did not reduce the production of a third LPS-triggered cytokine CXCL1, so the effect was not 
a toxic or global downregulation of the LPS response.  
The anti-inflammatory effects of a glutamine synthetase inhibitor were seen even though 
the medium contained abundant (2 mM) glutamine, suggesting that the target for this activity was 
not glutamine synthetase. In agreement with this hypothesis, the L,R isomer of MSO, which does 
not inhibit glutamine synthetase and was previously thought to be inert, both significantly reduced 
IL-6 secretion in isolated macrophages and increased survival in a mouse model for inflammatory 
liver failure. Our findings provide evidence for a novel target of MSO. Future attempts to identify 
the additional target would therefore also provide a target for therapies to treat diseases involving 
damaging cytokine responses. 
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Background 
Methionine sulfoximine (MSO) is an amino acid inhibitor of glutamine synthetase 
(GS)(1,100,101). In addition to its historical use in dissecting the mechanism of GS, this molecule 
has also been shown to have therapeutic effects in animal models of hepatic encephalopathy, 
amyotrophic lateral sclerosis (ALS), and inflammatory liver failure(102). For hepatic 
encephalopathy, MSO treatment reduces glutamine in astrocytes, preventing the osmotic swelling 
that results from ammonia-driven synthesis of glutamine from glutamate(7). For ALS, it appears 
that MSO reduces excitotoxicity by reducing the levels of both glutamine and glutamate in the 
brain(31,103). Additionally, MSO appears to have anti-inflammatory effects, since it increases 
survival in a mouse model for inflammatory liver failure resulting from exposure to 
lipopolysaccharide (LPS)(35). MSO reduces the LPS-induced cytokine response for several pro-
inflammatory cytokines, most notably tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6), 
two cytokines strongly associated with an array of inflammatory diseases(104,105). It was 
previously unclear to what extent these effects are mediated by glutamine synthetase inhibition, or 
if there is another target for this molecule. 
In order to determine the anti-inflammatory target(s) for MSO, we measured its effects on 
the cytokine response of isolated macrophages to LPS treatment, its effects on transcription of 
cytokine genes, the role of medium glutamine in MSO-inhibition of the cytokine response, and the 
effects of both the L,R and L,S stereoisomers of MSO on this anti-inflammatory action in vivo and 
in vitro. 
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Methods 
Ethics 
All animal experiments complied with Institutional Animal Care and Use Committee 
(IACUC) guidelines for animal welfare at Wayne State University. Male CD1 mice were 
purchased from Charles River (USA). All animals used for experiments were 6-10 weeks old. 
Rat Kupffer Cell Culture 
Cryopreserved Rat Kupffer cells (ThermoFisher Scientific, USA) were thawed in a 37°C 
water bath before being gently pipetted into 8 mL of ice cold Advanced DMEM Medium 
(ThermoFisher Scientific) containing 5% FBS (Gibco, USA) and 4% Thawing and Plating 
Cocktail A (Catalog No. CM3000, ThermoFisher Scientific). Cells were centrifuged at 500 x g for 
10 minutes at 4°C. The supernatant was discarded, and the cells were resuspended in 2 mL of 
medium and counted using a hemocytometer. Cells were seeded into 12-well plates at 4 x 105 cells 
per well and placed into a humidified incubator with 95% air, 5% CO2 at 37°C. 4 hours later the 
media was aspirated and cells were washed 3 times with warm PBS before 1 mL of RPMI 1640 
with GlutaMAXTM supplement and HEPES (ThermoFisher Scientific), containing 10% FBS and 
a 1% mixture of penicillin-streptomycin (ThermoFisher Scientific) was added to each well. Cells 
were incubated overnight (20-24 hours) before any experiments were performed. 
Mouse Peritoneal Macrophage Culture 
Peritoneal macrophages were isolated as previously described by Zhang et al. (2008) with 
minor modifications(106). Two mice were used for each experiment. After euthanasia, 10 mL of 
cold phosphate buffered saline (4°C) was injected into the peritoneal cavities of each mouse. The 
abdomens were gently massaged before a small incision was made within the abdominal wall and 
the exudate was aspirated using a disposable transfer pipette and transferred into a 15 mL conical 
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tube. Cell suspensions were centrifuged at 500 x g for 10 minutes at 4⁰ C. The supernatant was 
discarded, and the pellet was gently resuspended in 2 mL of Advanced DMEM Medium containing 
5% FBS and 4% Thawing and Plating Cocktail A on ice. Approximately 2 x 105 cells were added 
to each well of a 12-well tissue culture plate which was placed in a humidified incubator with 5% 
CO2 for 2 hours at 37° C. The media was aspirated, and cells were washed three times with warmed 
PBS before 1 mL of RPMI 1640 with GlutaMAXTM supplement and HEPES, containing 10% FBS 
and a 1% mixture of penicillin-streptomycin was added to each well. Cells were incubated 
overnight (20-24 hours) before any experiments were performed. 
Macrophage Activation 
All media and reagents were sterile filtered through a 0.22 micron syringe filter prior to 
use. L Methionine R,S-sulfoximine (Sigma, USA), and Lipopolysaccharides from Escherichia coli 
O111:B4 (Catalog No. L6230, Sigma), were dissolved in sterile PBS. Purified L,S and L,R MSO 
were purchased from Toronto Research Chemicals (Canada). Cells were divided into four 
treatments each with at least two biological replicates. Treatments consisted of LPS only, MSO + 
LPS, MSO only, and untreated. All cells in culture were washed 2-3 times with warm, serum-free 
RPMI 1640 with GlutaMAXTM supplement and HEPES before 0.5 mL of media, with or without 
MSO, was added to each well. After incubation for one hour, LPS (1 µg/mL) was added to the 
appropriate wells, and media samples were collected at different times for the measurements 
described in the different experiments. 
41 
 
 
 
Intracellular IL-6 measurement 
For intracellular protein quantification, the medium was removed, and cells were lysed 
directly within wells of the cell culture plate in 20 mM Tris buffer containing 100 mM NaCl, 1 mM 
EDTA, and 0.2% Triton X-100 (pH 7.4). After 20 minutes of incubation on ice, cells were scraped 
vigorously and observed under the microscope to ensure complete lysis. IL-6 within cell lysates 
was measured using the Mouse IL-6 Ready-SET-Go® ELISA kit (eBioscience, USA). 
IL-6 Immunofluorescence 
Cells were cultured on 8-well glass chamber slides (Millicell® EZ SLIDE 8-well glass, 
sterile, Catalog No. PEZGS0816, Millipore, USA) in the same manner as described for the 
experiments performed in tissue culture plates. Cells were pre-treated with 9 mM MSO for one 
hour prior to the addition of 1 µg/kg LPS. Cells treated with LPS alone served as positive controls, 
whereas cells treated with MSO alone or left untreated served as negative controls. After 6 hours 
of LPS stimulation, the medium was aspirated, and cells were washed three times with PBS before 
being fixed to the chamber slides with a 4% paraformaldehyde solution in PBS for 10 minutes. 
Cells were made permeable by the addition of a 0.1% Triton X-100 solution in PBS for 20 minutes, 
followed by an overnight incubation with a monoclonal antibody specific for mouse IL-6 (Cell 
signaling technology, USA, Catalog No. D5W4V) at 4 degrees. Cells were washed before 
incubation with an Alexa Fluor-conjugated secondary antibody (Abcam, USA, Catalog No. 
ab15007) in the presence of 10% goat serum (R&D systems, USA). A mounting medium 
containing the nuclear stain DAPI (Electron Microscopy Sciences, USA, Catalog No. 17985-50) 
was applied to a cover slip, and fluorescence was visualized under a confocal microscope. 
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Glutamine depletion experiments 
Cells were isolated and plated in 12-well plates in the conditions listed above. After 
overnight incubation, cells were washed 3 times with RPMI either containing glutamine or RPMI 
without glutamine. 0.5 mL of fresh, serum-free medium, with or without glutamine and MSO was 
added to each well one hour prior to the addition of LPS. Experiments were limited to 6 hours in 
consideration of the possibility that cell death could occur due to prolonged glutamine depletion. 
Enzyme Linked Immunosorbent Assay (ELISA) 
Mouse and Rat TNF-alpha Ready-SET-Go® ELISA kits, and Mouse IL-6 Ready-SET-Go® 
ELISA kits (eBioscience, USA) were used to assess the levels of TNFα and IL-6 in the macrophage 
activation experiments. Mouse CXCL1/KC DuoSet ELISA (R&D systems, USA) was used to 
measure mouse CXCL1 in all macrophage activation experiments. IL-10 Mouse Uncoated ELISA 
kit (ThermoFisher Scientific) was used to quantify IL-10. The procedures were carried out per the 
manufacturer’s instructions, and all data were analyzed using the Epoch microplate 
spectrophotometer and Gen5 data analysis software (Biotek, USA). 
Nitric Oxide (NO) Assay 
Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical, USA) was used to assess the 
concentration of NO secreted by macrophages into the culture medium. The procedures were 
carried out per the manufacturer’s instructions.  
Lactate Dehydrogenase (LDH) Assay 
LDH release from peritoneal macrophages was assessed with the Cytotoxicity Detection 
Kit (LDH) (Sigma Aldrich, USA) per the instructions provided by the manufacturer. For this assay, 
LDH activity is proportional to colorimetric reduction of tetrazolium salt measured at 490 nm. To 
serve as a positive control, a subset of cells was exposed to a Triton X-100 solution for 45 minutes, 
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and the average OD 490 nm measurement from these cells was considered as the maximum LDH 
activity (100%) and served to normalize LDH values obtained from cells treated with MSO. An 
additional subset of cells treated with dH2O, served as a negative control. 
RNA isolation and Reverse Transcription PCR (RT-PCR)  
Approximately 2 x 106 cells per well were plated in 6-well plates after peritoneal exudate 
cells were isolated in the media conditions (with or without MSO) and incubation times listed 
above. At 1, 3, or 5 hours after LPS addition cells were lysed and RNA was isolated using the 
contents provided within the RNeasy mini kit (Qiagen, Germany). The RNA concentration in each 
sample was measured with a Qubit® fluorometer, using the RNA high sensitivity kit (Thermofisher 
Scientific Catalog No. Q32852). Reverse transcription reaction was performed using the iScriptTM 
cDNA Synthesis Kit (Bio-Rad, USA). 250 ng of total RNA were used in each 20 uL reaction, with 
equal amounts of total RNA used for each sample. 
Quantitative real-time PCR (qRT-PCR) 
qRT-PCR was performed using a ready-to-use PowerUp™ SYBR® Green Master Mix 
(ThermoFisher Scientific). SYBR green fluorescence was detected by the 7500 Real Time PCR 
System (Applied Biosystems), using 25ng of cDNA per reaction. Gene expression was normalized 
to the expression of the reference gene, beta-actin (β-actin). Oligonucleotide primers for TNFα 
and IL-6 were previously designed and used by Simpson, Tomkins and Cooper (1997)(107). 
Primer sequences were purchased as lyophilized powder (Invitrogen, USA) and are as follows: 
IL-6 (forward: 5’-GAC AAA GCC AGA GTC CTT CAG AGA G-3’ and reverse: 5’-CTA GGT 
TTG CCG AGT AGA TCT C-3’), TNFα (forward: 5’-ATG AGC ACA GAA AGC ATG ATC-3’ 
and reverse: 5’-TAC AGG CTT GTC ACT CGA ATT-3’), β-actin (forward: 5’-GTG GGC CGC 
TCT AGG CAC CA-3’ and reverse: 5’-CGG TTG GCC TTA GGG TTC AGG GGG G-3’). The 
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quality of each PCR product was confirmed by melting curve analysis. Relative quantification of  
fold induction of TNFα and IL-6 mRNA was assessed using the ΔΔCt method described by Livak 
and Schmittgen (2001)(108). 
Acute Liver Failure Mouse Model 
We used an accepted method to induce acute liver failure into mice by co-injecting LPS 
(20 µg/kg) and D-galactosamine (800 mg/kg, Sigma, USA) intraperitoneally (IP). 3 hours prior to 
injecting LPS/D-Gal, mice were injected IP with either saline (negative control), L,S MSO 
(25 mg/kg), or L,R MSO (25 mg/kg). Food was removed from the cages prior to any injections, 
but mice were allowed access to water throughout the duration of the experiment. Mice that failed 
to respond to prodding and right themselves were euthanized. Survival was monitored for 24 hours. 
Statistical analysis 
Values are expressed as mean ± standard error (s ± SEM). All experiments were repeated 
at least three times. T-tests were performed for analyses of statistical significance in cell culture 
experiments. For the mouse experiments, differences in survival between groups were assessed 
using Fisher’s exact test. All statistical analyses were performed using IBM SPSS Statistics version 
24 for Windows. Differences between treatments were considered significant when p < 0.05. 
Results: 
We have previously shown that treatment of mice with MSO reduces the LPS-induced 
production of cytokines TNFα, IL-6, and IFγ in vivo(35). In this report, we describe the effects of 
MSO on IL-6 and TNFα production by isolated macrophages treated with LPS. 
Effect of MSO on IL-6 production 
We first determined the minimal effective concentration for inhibiting the LPS-triggered 
IL-6 response by treating cells cultured in normal medium (2 mM glutamine) with either 9 mM, 
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4.5 mM, or 1 mM MSO for one hour before the addition of LPS (1 µg/mL) to the culture medium. 
Figure 6A shows that in two independent experiments, 9 mM MSO appeared to be the minimum 
effective concentration required to significantly reduce IL-6 in the culture medium of LPS-
stimulated mouse peritoneal macrophages at 4 and 6 hours after LPS exposure. These data suggest 
that a dose-dependent relationship might exist, with 9 mM MSO being the most effective in 
reducing IL-6 secretion, 1 mM being ineffective, and 4.5 mM falling in between. IL-6 levels in the 
culture medium of untreated cells or cells treated with MSO alone were undetectable (not shown).  
Effect of MSO on cellular and secreted IL-6 
The observed effect of MSO on the production of secreted IL-6 resulted from either 
decreased synthesis or decreased secretion.  We therefore compared IL-6 levels in the culture 
medium to IL-6 levels measured in cell lysates. IL-6 levels measured in the medium were much 
higher than in the cell lysates for all samples. 4 hours after LPS treatment, the amount of IL-6 in 
the supernatant was approximately 3 times greater in the supernatant than in the lysate (3.8X for 
LPS-only controls and 2.9X for MSO-treated cells). At 6 hours, the IL-6 measured in the 
supernatant was over 10 times greater than inside the cells (16.6X for LPS-only controls and 
11.2X for MSO-treated cells). 
Figure 6B shows that, when compared to controls, the % decreases of IL-6 resulting from 
MSO-treatment were similar in both the medium (secreted) and the cell lysate (intracellular). MSO 
treatment reduced secreted and intracellular IL-6 concentrations at both 4 and 6 hours after LPS 
addition. At 4 hours, a mean 33% reduction of IL-6 was observed in the medium of MSO treated 
cells, compared to a mean 20% reduction of IL-6 in the lysates. At 6 hours, a mean 45% reduction 
of IL-6 was observed in the medium of MSO treated cells compared to a mean 42% reduction of 
IL-6 in the lysates. MSO-treatment therefore did not result in cells “filling up” with cytokine. 
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To further demonstrate that the decrease in medium IL-6 could be attributed to decreased 
levels of IL-6 within the cells, we used immunofluorescence to visualize IL-6 in MSO-treated and 
untreated cells 6 hours after LPS treatment (Figure 1C). In agreement with the results shown in 
Figure 6B, Figure 6C demonstrates a clear reduction of cytoplasmic IL-6 with MSO treatment 
when compared to cells treated with LPS only. 
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Figure 6. Effects of MSO on IL-6 production. A, dose-dependent effects of MSO on LPS-
triggered IL-6 production (s ± SEM). Peritoneal macrophages were treated with three 
concentrations of MSO one hour prior to the addition of 1 µg/mL LPS, and IL-6 production in the 
medium was quantitated by ELISA 4 hours and 6 hours after LPS treatment (n=6, *p < 0.05). B, 
effects of MSO on intracellular and extracellular IL-6 production. Cells were treated with 9 mM 
MSO, and in addition to measuring IL-6 in the medium after LPS treatment, cells were washed, 
lysed, and the amount of IL-6 in the lysate was quantitated as a measure of intracellular IL-6. 
Untreated cells, or cells treated with MSO alone (minus-LPS) did not produce detectable levels of 
IL-6. ELISA values obtained from LPS stimulated control (minus-MSO) samples were normalized 
as 100%, and the average amounts of IL-6 produced in the treated supernatant and lysate samples 
are indicated as percentages of the controls. These data represent averages from 3 additional 
macrophage preps different from those represented in A, with three biological replicates for each 
treatment. *p < 0.05, **p < 0.01, ***p < 0.001. C, immunofluorescence detection of intracellular 
IL-6 protein, 6 hours after LPS treatment. The top row shows, from left to right, levels of 
intracellular IL-6 in untreated cells, cells treated with LPS, treated with LPS and MSO, or treated 
with just MSO.  The same cells were also stained with the nuclear stain DAPI, and the two 
fluorescent images were merged in the bottom row, showing that the nuclei of treated and untreated 
cells appear the same. 
Effect of MSO on production of TNFα 
Peritoneal macrophages also produce TNFα after LPS stimulation. Figure 7A shows LPS-
stimulated production of TNFα in cells treated with MSO after 4, and 6 hours. We found no 
significant effects after 2 hours (not shown). Compared to cells treated with LPS alone, cells 
pretreated with MSO showed significant reductions in TNFα secreted into the culture medium at 
4 hours (reduced by 40% ±7%) and 6 hours (reduced by 38% ± 8%).  
As an added test of the ability of MSO to inhibit TNF-a production, we carried out these 
same assays in commercially available rat Kupffer cells (see Methods). Kupffer cells are the 
resident liver macrophages responsible for inflammatory liver failure(109). They respond to LPS 
by producing cytokines including IL-6 and TNFα. Rat Kupffer cells are commercially available, 
but when we tested the effects of MSO on cytokine production by those cells, we found batch-to-
batch variability in the LPS-triggered responses. Most of the preparations that we purchased (five 
out of eight) responded to LPS treatment and produced TNFα, as they should. In those 
experiments, we could observe a significant decrease in TNFα secretion when these cells were pre-
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treated with MSO. Figure 7B shows inhibition by MSO of LPS-triggered TNFα production in 
primary rat Kupffer cell cultures (s ± SEM), with 58% ± 9% and 45% ± 3% mean decreases in 
TNFα secretion after 4 and 6 hours, respectively. 
However, several batches of these commercially-available cells (three out of eight) did not respond 
to LPS, indicating that these cell preparations were of poor quality. The substantial batch-to-batch 
variability led us to concentrate instead on the peritoneal macrophage preparations for essentially 
all of our studies besides those shown in Fig. 2B, which shows the results obtained only from those 
batches of cells that demonstrated significant production of TNFα when treated with LPS alone. 
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Figure 7..Effect of MSO on TNFα production. TNFα secretion by (A) primary mouse peritoneal 
macrophages and (B) primary rat Kupffer cells after incubation in the presence or absence of MSO 
and LPS. Untreated cells, or cells treated with MSO alone (minus-LPS) did not produce detectable 
levels of TNFα. The level of TNFα induction by LPS stimulated controls, was normalized to 100%. 
A, mean TNFα protein concentration in LPS-stimulated controls was 114 pg/mL at 4 hours and 
183 pg/mL at 6 hours. B, mean TNFα protein concentration of LPS stimulated controls was 
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71 pg/mL at 4 hours and 117 pg/mL at 6 hours. These data represent 3 peritoneal macrophage 
preparations and 5 Kupffer cell preparations. Each preparation contained at least 2 biological 
replicates for each treatment. **p <0.01, ***p <0.001 
Effect of MSO on transcription of TNFα and IL-6 
The expression of the genes for TNFα and IL-6 has been shown to peak between 1 and 3 
hours after LPS stimulation in mouse peritoneal macrophages(107). To test if MSO affected 
transcription of TNFα or IL-6, cells were treated with LPS for up to 5 hours, then lysed and the 
mRNA was isolated, reverse-transcribed into cDNA, and subjected to quantitative PCR, with 
relative β-actin level serving as an endogenous control. Both IL-6 and TNFα mRNA levels were 
unaffected by MSO (Figure 8), suggesting that the inhibitory action of MSO on the production of 
these proteins does not occur at the level of gene expression. 
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Figure 8. Effect of MSO on transcription of the cytokine genes. Mouse peritoneal macrophages 
were treated with MSO, then LPS as indicated for the experiments in Figure 1 and Figure 2. At 1, 
3, or 5 hours after LPS treatment, cells were, harvested, lysed, and mRNA was isolated as 
described in Methods. qRT-PCR was conducted using primers specific for either TNFα or IL-6. 
Relative mRNA levels are plotted as ΔΔCt, the log2 transformed fold increase in mRNA compared 
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to untreated cells (108). Data from each timepoint were obtained from at least 3 experiments, with 
all technical replicates shown for clarity. 
Effect of MSO on other important macrophage functions 
In addition to secreting pro-inflammatory cytokines, macrophages perform other essential 
functions to initiate, maintain, and resolve immune responses to infection. A central function of 
macrophages is to phagocytose and digest foreign antigens, namely through the production of 
reactive nitrogen species(110). LPS stimulated macrophages express an inducible nitric oxide 
synthase whose expression has been shown to be regulated by other cytokines, namely TNFα and 
IL-1β(111). Since MSO profoundly reduced TNFα secretion by peritoneal macrophages, we tested 
to see whether MSO could affect the production of NO by these cells. Nitric oxide is highly 
reactive; upon production it is quickly reduced to the more stable compounds nitrate and nitrite. 
Using a commercially available kit, we detected the total level of nitrate and nitrite secreted by 
macrophages stimulated with LPS for 24 hours, in the presence or absence of MSO. Figure 9A 
shows that MSO did not have any appreciable effect on the level of NO production by these cells, 
suggesting that MSO treated cells maintain the ability to carry out other functions, and that the 
effects of MSO appear to be specific 
Activated macrophages secrete several chemotactic proteins that recruit neutrophils and 
other immune cells to an infected area, along with promoting angiogenesis(112). One such protein 
secreted by macrophages with chemotactic properties is CXCL1(113). As a chemokine, it is also 
involved in the inflammatory response mediated by macrophages.  We used the same type of 
ELISA assay to measure LPS-induced CXCL1 production in the presence or absence of MSO and 
found no effect (Fig. 9B). LPS was required to induce CXCL1 production; untreated cells or cells 
treated with MSO alone (minus-LPS) did not produce detectable levels of CXCL1.  
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In order to resolve inflammation once foreign agents are eliminated, macrophages secrete 
proteins that are critical in limiting immune mediated responses(114). The major anti-
inflammatory cytokine secreted by macrophages is interleukin 10 (IL-10). IL-10 secretion induces 
T cell hypo-responsiveness, and down regulates TNFα production, and in peritoneal macrophages 
has been demonstrated to peak approximately 24 hours after LPS stimulation(115). We treated 
peritoneal macrophages with LPS for 24 hours (+/- MSO) and used ELISA to quantify the 
concentration of IL-10 in the supernatant (Figure 9C). MSO had no effect on the production of 
IL-10 compared to controls, suggesting that MSO treated cells remain capable of eliciting anti-
inflammatory functions.  
We have recently shown that MSO does not globally down regulate protein synthesis and 
has negligible effects on the total level of secreted proteins (116). This finding, in agreement with 
the results shown in Figure 9, suggest that MSO specifically down-regulates TNFα and IL-6, does 
not globally downregulate cellular function in response to LPS, and is safe to use at a concentration 
of 9 mM, as was shown in other laboratories(117-119). 
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Figure 9. Effects of MSO on NO production, CXCL1 secretion, and IL-10 secretion. A, mouse 
peritoneal macrophages were treated with MSO or left untreated before being stimulated with LPS 
for 24 hours and the concentration of NO in the culture medium was quantified using a 
commercially available kit (n=3). The mean NO secreted into the medium after 24 hours (s ± SEM) 
was 2.92 ± 0.1 for LPS controls, and 2.55 ± 0.15 for MSO treated cells (difference not significant). 
NO was not detectable in the medium of cells left untreated or treated with MSO alone. B, effect 
of MSO on LPS-triggered production of the cytokine CXCL1 (n=3).   Experiments were carried 
out as described for Figure 1 and Figure 2.  ELISA was used to quantitate LPS-triggered production 
of CXCL1 in the presence or absence of MSO 4 hours and 6 hours after LPS treatment. CXCL1 
was not detectable in the medium of untreated cells, or for cells treated with MSO alone (minus-
LPS). The mean CXCL1 protein concentration measured in LPS stimulated controls was 450 
pg/mL at 4 hours and 750 pg/mL at 6 hours.  Control values were normalized to 100%, and average 
values from treated samples were plotted in comparison to those controls. C, effect of MSO on 
LPS-triggered production of the anti-inflammatory cytokine IL-10 (n=3). Experiments were 
carried out as described for Figure 1 and Figure 2.  ELISA was used to quantitate LPS-triggered 
production of IL-10 in the presence or absence of MSO 24 hours after LPS treatment. IL-10 was 
not detectable in the medium of untreated cells, or for cells treated with MSO alone (minus-LPS). 
The mean IL-10 protein concentration measured in LPS stimulated controls was 1293 pg/mL. 
Control values were normalized to 100%, and average values from treated samples were plotted 
in comparison to those controls 
Finally, to rule out other nonspecific effects of MSO on cell viability such as perturbations 
in osmotic pressure and plasma membrane integrity, we treated cells with a range of MSO 
concentrations from 1 to 100 mM and determined cytotoxicity by measuring lactate dehydrogenase 
activity released into the culture medium(120).  MSO concentrations of up to 100 mM were non-
toxic in this assay (Table 5). 
Parameter Triton X-100 dH20 1 mM 10 mM 20 mM 50 mM 100 mM 
OD (490 nm) 0.8 0.04 0.04 0.05 0.03 0.03 0.03 
% Cytotoxicity 100 0 0 0 0 0 0 
Table 5. MSO is non-toxic to cells at high doses. Lactate dehydrogenase (LDH) activity in the 
medium of cells treated with 1 to 100 mM MSO. Cells were treated with concentrations of MSO 
ranging from 1 to 100 mM for 2 hours or left untreated. Afterwards, cells were treated with Triton 
X-100 (positive control), or dH2O (negative control), and incubated for an additional 45 minutes 
before LDH activity in the medium was assessed. LDH activity was completely absent in the 
medium of cells treated with up to 100 mM MSO, indicating that MSO was not cytotoxic.  100 
mM MSO had no inhibitory effect on purified, recombinant LDH (not shown). See methods for a 
more complete description of this assay. 
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Role of medium glutamine on MSO transport and its effect on IL-6 production 
MSO is a glutamine/glutamate/methionine analogue, and it has been demonstrated that 
glutamine and methionine can compete with MSO for transport into cells in different prokaryotes 
(121,122).  Additionally, glutamine is known to enhance the function of immune cells(123). Levels 
of medium glutamine and cellular glutamine metabolism are therefore complicating factors for in 
vitro cell culture experiments involving MSO.  The experiments described above were all carried 
out in medium containing 2 mM glutamine. We therefore attempted to dissect the role of medium 
glutamine in the observed responses by first measuring LPS-triggered production of IL 6 
(+/- MSO) in medium containing different concentrations of glutamine (Figure 10A). 
When glutamine was removed from the medium, LPS-stimulated IL-6 secretion by isolated 
peritoneal macrophages was reduced by approximately 50% compared to production in medium 
containing glutamine, commensurate with observations from other laboratories. More importantly, 
the effect of 9 mM MSO was more pronounced in the absence of medium glutamine. The effect 
of MSO on IL-6 production was the same in media containing 1, 2, and 4 mM glutamine.  
We then tested the effect, in the absence of glutamine, of the lower concentrations of MSO 
(4.5 mM and 1 mM), that previously had little or no effect on IL-6 production in the presence of 
glutamine (see Figure 6B). Figure 10B shows that when glutamine was absent, all 3 of the tested 
MSO concentrations yielded significant reductions in medium IL-6, 6 hours after the cells were 
stimulated with LPS, with no significant difference between the % reduction of IL-6 between any 
of the concentrations. 
This increase in potency was reversed by the addition of 0.5 mM glutamine to the culture 
medium (data not shown). The fact that MSO potency increases substantially in the absence of 
glutamine is most likely explained by the presence of a common transport system for MSO and 
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glutamine, as was seen for S. enterica (121), although competition between MSO and glutamine 
for transport has not been studied in murine macrophages. 
 
Figure 10. Effect of medium glutamine on IL-6 response to LPS and MSO. (A) Peritoneal 
macrophages were prepared as previously described but were incubated in medium glutamine 
concentrations ranging from 0 to 4 mM one hour prior to the addition of LPS. As indicated, cells 
were also treated with 9 mM MSO. At 6 hours after LPS treatment, IL-6 in the culture medium 
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was assayed by ELISA. (s ± SEM, n=6) (B) Peritoneal macrophages were treated with either 1, 
4.5, or 9 mM MSO in medium lacking glutamine for 1 hour prior to a 6-hour exposure to LPS. 
Control values were normalized to 100%, and average values from treated samples were plotted 
in comparison to those controls. All 3 of the tested MSO concentrations yielded significant 
reductions in medium IL-6, with no significant difference between the % reduction of IL-6 
between any of the concentrations. 
Role of glutamine synthetase in MSO mediated cytokine suppression 
It is apparent that extracellular glutamine enhances LPS-stimulated IL-6 production in 
vitro, but it is not clear to what extent, if any, that MSO is acting to inhibit IL-6 secretion through 
inhibiting the intracellular production of glutamine, because – aside from these experiments 
measuring dependence on glutamine concentration - in all of our other experiments extracellular 
glutamine (2 mM) is present in the medium, and MSO concentrations above its  Ki for glutamine 
synthetase still inhibit cytokine production. We feel it is therefore unlikely that the effect depends 
on MSO targeting glutamine synthetase.  Nonetheless, we carried out an additional test of the role 
of GS inhibition in the observed anti-inflammatory effects of this drug by testing different 
stereoisomers of MSO. Commercial preparations of MSO contain a racemic mixture of two 
diastereomers – L,S and L,R, but only the L,S isomer inhibits glutamine synthetase activity (124). 
To validate the purity of the isomers and to establish GS inhibition, we tested the effect of 
purified formulations of both the L,R and L,S diastereomers of MSO, along with the commercial 
racemic mixture, on mouse liver GS activity using an established GS enzyme assay(125). We 
treated mouse liver homogenates with either 1 mM of the racemic mixture, or 0.5 mM of each 
purified isomer.  As was first shown in 1969 (101)we found that the L,S isomer inhibited glutamine 
synthetase, and the L,R did not (not shown). 
We performed experiments using purified formulations of both L,R and L,S diastereomers 
of MSO in normal glutamine-containing culture medium (Figure 11A and 11B). Both isomers 
showed a similar dose-dependent response, with 9 mM significantly reducing IL-6 at both time 
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points, whereas 4.5 mM only showed significant IL-6 reduction at 6 hours, and 1 mM was 
ineffective at both time points. As one would expect if glutamine synthetase were the sole target, 
the L,S isomer significantly reduced IL-6 production at both 4 and 6 hours after cells were 
stimulated with LPS (Figure 11B). However, this effect could only be achieved using 9 mM of 
purified isomer, twice the concentration present in a racemic mixture, assuming a 50:50 mix of 
diastereomers. Strikingly, under normal medium conditions, the L,R isomer at 9 mM was also 
shown to independently reduce IL-6 in the culture medium to a significant degree at both time 
points tested (Figure 11A). Both isomers therefore inhibit the in vitro cytokine response seen in 
isolated macrophage preparations. 
Figure 11A and 11B illustrate the variability in response from different preparations of 
macrophages made from different batches of mice. Although the percent inhibition by MSO is 
consistent across all experiments, the LPS response of the positive controls (minus-MSO) can vary 
2-3 fold depending on the batch of mice and the age of the mice. It also varies because the 
harvesting of macrophages involves peritoneal lavage, which sometimes harvests a significant 
number of non-macrophage cells.  These differences can result in plating different numbers of 
actual macrophages, even though the number of cells plated is the same. 
When glutamine was removed from the culture medium 1 hour prior to the addition of LPS, 
L,R-MSO (Figure 11C) and L,S-MSO (Figure 11D) at a concentration of 1 mM, significantly 
reduced IL-6 in the culture medium at both 4 and 6 hours after LPS exposure, as was the case with 
the racemic mixture as seen in Figure 5. Significantly, 4.5 mM of either isomer was ineffective 
alone in normal culture medium but was effective in reducing IL-6 secretion when combined as a 
9 mM racemic mixture. The fact that the L,R isomer significantly reduces IL-6 production but does 
not inhibit GS, combined with the fact that MSO can inhibit cytokine production even in the 
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presence of substantial medium glutamine,  strongly suggests that glutamine synthetase is not the 
most important functional target that inhibits cytokine production in the presence of MSO, if in 
fact it is a functional target at all. 
 
Figure 11. Concentration dependent effect of purified MSO isomers on IL-6 secretion 
(s ± SEM). Under normal medium conditions (2 mM glutamine), peritoneal macrophages were 
exposed to either 1, 4.5, or 9 mM of R-MSO (A) or S-MSO (B) one hour prior to the addition of 
LPS. At 4 and 6 hours after LPS addition, the medium was harvested and IL-6 was quantified 
using ELISA. As observed with the racemic mixture, only 9 mM of either isomer caused 
significant decreases in IL-6 at both time points tested. However, 4.5 mM of either L,R or L,S 
MSO caused a significant decrease in IL-6 after 6 hours of LPS stimulation. Removing glutamine 
from the culture medium resulted in an increase of potency of both isomers, as L,R (C) and L,S 
(D) MSO at a concentration of 1 mM significantly reduced IL-6 secretion in the culture medium 
at both time points tested. 
This in vitro activity of the L,R isomer led us to test its activity in vivo, in the same mouse 
model for liver failure used previously, to show that racemic MSO could protect mice against death 
from liver failure resulting from an inflammatory immune response(8).  We repeated those 
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experiments using the purified isomers, and the results are shown in Table 5. Both isomers were 
capable of significantly increasing survival in mice injected with LPS and D Galactosamine to 
induce fatal liver failure caused by an inflammatory immune response. 
Treatment Alive Dead Total (n) 
Percent 
Survival (%) pa 
Saline 3 19 22 14 - 
L,S MSO (25 mg/kg) 19 9 28 68 0.0002 
L,R MSO (25 mg/kg) 18 12 30 60 0.0013 
Table 6. MSO isomers prevent LPS induced lethality in mice. 24 hour survival analysis of mice 
injected with saline, L,R MSO (25 mg/kg), or L,S MSO (25 mg/kg) 3 hours prior to injection of 
LPS (20 µg/kg) and D-Galactosamine (800 mg/kg). a = determined by Fisher’s exact test. 
Discussion 
The production of IL-6 and TNFα is essential in mediating the innate immune response to 
infection(66,74), as well as regulating other important homeostatic processes such as wound 
healing(126) and sleep(127,128). However, during acute inflammatory crises, overproduction of 
these and other cytokines can compromise the self-limiting ability of innate immunity and can 
result in a damaging and occasionally fatal outcome. As such, serum IL-6 levels were shown to be 
highly valuable in the diagnosis of infection and the prognosis of critically ill ICU patients 
(76,129). Macrophages are the main source of these cytokines, which act in concert to initiate the 
acute phase response by hepatocytes(75), to increase vascular permeability(68), and to amplify 
inflammatory responses through a variety of immune cell types. TNFα and IL-6 collectively 
exacerbate the immune response and its effects on multiple organ systems. 
MSO is a well-characterized inhibitor of glutamine synthetase(1,3,101). Our previously 
published studies on the anti-inflammatory effects of this drug in vivo raised the obvious question 
of how glutamine synthetase inhibition might be responsible for the observed effects. The in vitro 
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studies described here have enabled us to dissect this process in additional and greater detail. These 
studies have demonstrated that glutamine plays an important role in both the overall cytokine 
response –shown previously(130,131) – and that glutamine levels can modulate how well MSO 
inhibits that cytokine response.  
When we substituted glutamine-free medium 1 hour prior to the addition of LPS, we 
observed a 50% decrease of IL-6 in the culture media compared to cells treated with LPS in 
medium containing glutamine. The combination of MSO treatment, which decreases glutamine 
synthetase activity, along with depletion of extracellular glutamine caused the largest decrease in 
IL-6 secretion that we observed in our experiments (Figure 10A), suggesting that the anti-
inflammatory mechanism might involve glutamine deprivation. Further, since those  results 
suggest that glutamine in the medium might compete with MSO for transport into the cell, then 
the reverse competition – MSO competing with glutamine for uptake, albeit weakly, since it takes 
9 mM MSO to show an effect in the presence of 2 mM glutamine – might partially explain the 
anti-inflammatory effect, if MSO reduces cellular glutamine uptake and therefore reduces the 
cytokine response.   
However, the demonstration that 1) high levels of MSO can inhibit the response even in 
the presence of 2 mM medium glutamine (conditions where glutamine synthetase would not be 
needed), and 2) the L,R isomer has anti-inflammatory activity on its own, despite not inhibiting 
glutamine synthetase, means that there is another target for this drug to affect the inflammatory 
response. MSO may therefore be influencing some aspect of glutamine metabolism important to 
cytokine production, either by inhibiting glutamine synthetase, inhibiting glutamine transport, or 
acting on some other unknown target that might or might not involve glutamine metabolism, or 
some combination of these two potential targets.   
63 
 
 
 
As analogues of glutamine, glutamate, and methionine, either or both isomers could be 
binding to a receptor or transporter for any of these amino acids and exerting their effects through 
a variety of signaling pathways.  These important questions are not addressed by these studies, but 
answering them could identify a target or targets that could be useful in treating the deleterious 
side effects of a cytokine storm resulting from an inflammatory immune response. 
Conclusions 
1) MSO treatment reduces the LPS-stimulated production of IL-6 and TNFα in vitro, in 
agreement with our previously published in-vivo results. 2) This effect is specific and not the 
result of toxicity or overall downregulation of the response to LPS, 3) MSO does not act on 
transcription, but may be acting on translation or on cytokine turnover and 4) the L,R isomer of 
MSO, which does not inhibit glutamine synthetase, has the same anti-inflammatory activity as 
the L,S isomer, and independently increases survival significantly in an established mouse model 
of acute liver failure. 
If glutamine synthesis is the sole limiting factor in IL-6 production, the L,R isomer 
should not have any activity in these assays. Although it appears possible that glutamine and 
MSO compete for transport, as the concentration needed to reduce IL-6 by both isomers 
decreased 10-fold in the absence of extracellular glutamine, such competition, if it occurs, cannot 
account for the effects of both isomers of MSO on the cytokine response in medium lacking 
glutamine.  Preliminary experiments in our lab measuring the IL-6 response have demonstrated 
EC50 values of sub-millimolar concentrations of MSO in medium lacking glutamine (not shown). 
Therefore, it appears that the anti-inflammatory effects of MSO involve some target besides, or 
perhaps in addition to, glutamine synthetase or glutamine transport.   Future attempts to identify 
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this target would therefore also provide a target for therapies to treat diseases involving 
potentially damaging cytokine responses. 
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CHAPTER 4 
Conclusions, current progress, and future directions 
The data presented in Chapter 3 indicate that glutamine synthetase is not the sole target of 
methionine sulfoximine in reducing pro-inflammatory cytokines secreted by murine macrophages. 
Additionally, since the L,R isomer of MSO can prevent lethality in a mouse model of acute liver 
failure, without causing neurological side effects associated with glutamine synthetase inhibition, 
this begs the question of how MSO is acting at the biochemical level.  In this Chapter, I will present 
current directions, unpublished preliminary data, and will propose a mechanism for how MSO 
might be decreasing the synthesis of pro inflammatory cytokines, based on several key findings 
that have occurred in the last 40 years. 
Methods 
Mouse Peritoneal Macrophage Culture 
Peritoneal macrophages were isolated as previously described in Chapter 3 with minor 
modifications. Four mice were used for each experiment. After euthanasia, 4 mL of cold phosphate 
buffered saline (4°C) was injected into the peritoneal cavities of each mouse. The abdomens were 
gently massaged before a small incision was made within the abdominal wall and the exudate was 
aspirated using a disposable transfer pipette and transferred into a 15 mL conical tube. Cell 
suspensions were centrifuged at 500 x g for 10 minutes at 4⁰ C. The supernatant was discarded, 
and the pellet was gently resuspended in 6 mL of Advanced DMEM Medium containing 5% FBS 
and 4% Thawing and Plating Cocktail A on ice. Cells were grown on Poly-D-Lysine coated glass 
coverslips (Neuvitro Corporation, USA) placed in the bottom of each well of a 6-well tissue culture 
plate. 1 mL of cell suspension was pipetted onto each cover slip and that culture plate was placed 
in a humidified incubator with 5% CO2 for 2 hours at 37° C. The media was aspirated, and cells 
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were washed three times with warmed PBS before 1 mL of RPMI 1640 with GlutaMAXTM 
supplement and HEPES, containing 10% FBS and a 1% mixture of penicillin-streptomycin was 
added to each well. Cells were incubated overnight (20-24 hours) before any experiments were 
performed. 
Radioactive glutamine transport 
Glutamine transport was measured on mouse peritoneal macrophages grown on glass 
coverslips by techniques similar to those described by Oxender et. al.(132). The coverslips were 
removed with forceps and submerged into a 1 x PBS solution to remove dead cells. The cells were 
placed into another 6 well plate containing 1 mL of uptake medium which consisted of phosphate 
buffered saline containing 0.1% glucose a mixture of [14C]-labeled (New England Nuclear, USA) 
and unlabeled glutamine (ThermoFisher Scientific) and Lipopolysaccharides from Escherichia 
coli O111:B4 (Catalog No. L6230, Sigma, USA). The total glutamine concentration for these 
experiments ranged from 500 nm to 4μM. After rinsing, the coverslips containing the cells were 
placed into uptake media in 5-minute intervals for up to 15 minutes at 25⁰C. The incubations were 
terminated by rinsing the coverslips twice in 1 x PBS before placing them into 0.5 mL of 200 mM 
NaOH to dissolve the cells. A 200 uL sample was removed for determining the radioactivity and 
another 200 uL sample was assayed for total protein content by the method of Lowry et al. Uptake 
of glutamine in cells treated with LPS alone was compared to cells incubated in the presence of 1 
mM racemic MSO (Sigma, USA). 
Interleukin 12 (IL-12) Enzyme Linked Immunosorbent Assay (ELISA) 
Mouse peritoneal macrophages were grown in 6-well tissue culture plates at a density of 
approximately 1.5 x 106 cells per well. Macrophages were treated with MSO or left untreated for 
1 hour followed by the addition of LPS (1μg/mL). Samples of culture media were analyzed for the 
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presence of IL-12 after 24 hours using the IL-12/IL-23 p40 (Total) Mouse Uncoated ELISA 
(ThermoFisher Scientific). The procedures were carried out per the manufacturer’s instructions, 
and all data were analyzed using the Epoch microplate spectrophotometer and Gen5 data analysis 
software (Biotek, USA). 
Preparation of mouse liver lysate 
Liver lysates from 4-8 week old male CD1 mice (Charles River, USA) were prepared to 
provide a protein mixture for MSO affinity chromatography. 2 mice were euthanized before the 
livers were removed, placed within a steel strainer and minced into pieces using sterile scissors. 
The fragmented livers were rinsed with PBS to remove as much blood as possible before being 
transferred to glass tubes in 3 mL of a PBS lysis buffer, pH 7.4, containing 100 mM NaCl, 0.1 M 
EDTA, 1% NP-40 and a cocktail of protease inhibitors (Roche, Switzerland). The livers were 
homogenized using a glass Teflon homogenizer on ice. Liver lysates were centrifuged for 15 
minutes at 1,000 x g to sediment cellular debris. The supernatant was aspirated with a syringe and 
sterile filtered using a 0.22-micron syringe filter. Total protein content was calculated using the 
Coomassie (Bradford) Protein Assay Kit (ThermoFisher Scientific). 
MSO pull-down assay 
The N-terminus of racemic MSO, L,S-MSO, and L,R-MSO was covalently cross-linked to 
N-hydroxysuccinimide linked beads marketed as Affi-Gel 10 (Bio-Rad), according to the 
manufacturer’s instructions. The following procedure was performed at 4⁰C. To 5 mL affinity 
chromatography columns, 3 mL of a 50% Aff-Gel: isopropyl alcohol suspension was added and 
quickly rinsed with 50 mL of dH2O followed by 50 mL of 50 mM MOPS buffer, pH 8. 100 mM 
MSO solutions in MOPS buffer, pH 8 were added to the columns. The gel-MSO mixtures were 
gently shaken overnight. The MSO solutions were eluted, and the columns were rinsed 3 times 
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with 50 mL MOPS buffer. The gels were incubated with a 1 mg/mL solution of BSA for 1 hour to 
block potential unreacted sites and to prevent non-specific reactions. The gels were rinsed with 50 
mL of MOPS, an equal volume of MOPS was added to the columns to create a 50% suspension, 
and 500 uL aliquots of these suspensions were pipetted into Eppendorf tubes. The same cross-
linking reaction was performed using a 1 M polyethanolamine solution, pH 8 as a negative control. 
50 uL samples of 50% Affi-Gel 10 reacted with either MSO or polyethanolamine were added to 
0.5 mL PCR tubes and centrifuged at 2000 RPM for 2 minutes. The supernatant was removed, and 
the gels were incubated overnight with 0.5 mL of 30 mg/mL mouse liver lysate on a laboratory 
rotator. Samples were centrifuged at 2000 RPM for 2 minutes, the supernatants were discarded, 
and the gels were resuspended in 600 uL of wash buffer consisting of 1 x PBS, 100 mM NaCl, 1% 
NP-40, pH 7.4. This process was repeated for a total of 5 washes before the supernatants were 
removed and 20 uL of 2 x Laemmli sample buffer was added to each sample. The samples were 
subjected to SDS-PAGE at 100 V using 10% polyacrylamide gels. The gels were stained using the 
Silver Stain Kit (Bio-Rad) per the manufacturer’s instructions. 
Results (Preliminary Data) 
Effect of MSO on glutamine transport 
When glutamine is removed from culture medium one hour prior to stimulating the cells 
with LPS, the concentration of IL-6 secreted by these cells is about half of what is seen when 
extracellular glutamine is available. In addition, when glutamine is removed from culture medium, 
the amount of MSO necessary to significantly reduce IL-6 secretion decreases from 9 mM to sub-
micromolar concentrations (a 500-fold reduction on average). Adding glutamine to the medium 
eliminates this apparent increase in MSO potency. This lead us to test if MSO competes with 
glutamine for transport into the peritoneal macrophages after LPS stimulation. 
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We tested the ability of 1 mM MSO to inhibit the transport of [14C] glutamine into mouse 
peritoneal macrophages stimulated with LPS for up to 15 minutes. For these assays we tested four 
concentrations of glutamine ranging from 1 to 4 μM in the presence and absence of 1 mM MSO. 
Figure 12 is a Lineweaver Burke plot of 1 divided by nanomoles of [14C] glutamine transported 
into cells per minute per microgram of total protein versus 1 divided by the concentration of total 
glutamine. These preliminary results suggest that 1 mM MSO might competitively inhibit 
glutamine transport in these cells. In mammals, there are 14 families of amino acid transport 
proteins capable of transporting glutamine across the plasma membrane(133). Therefore, only 
apparent Vmax and Km values could be approximated in these preliminary in vitro studies.  
The apparent Vmax and Km of glutamine transport in LPS stimulated cells (minus MSO) 
was approximated to be 0.22 nmol gln/min/μg total protein and 5.9 μM glutamine, respectively. 
The apparent Vmax and Km of glutamine transport in LPS stimulated cells in the presence of MSO 
was approximated to be 0.12 nmol gln/min/μg total protein and 16.7 μM glutamine, respectively. 
MSO treatment produced a plot that resembles competitive inhibition. However, more 
concentrations of glutamine must be tested to improve the accuracy and ensure reproducibility of 
these results. 
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Figure 12. Glutamine transport in LPS stimulated mouse peritoneal macrophages. Mouse 
peritoneal macrophages were stimulated with LPS in the presence or absence of MSO and the 
average rate of [14C] glutamine uptake was recorded (n=3). Four concentrations of glutamine were 
tested, ranging from 1 to 4 μM. MSO treatment appeared to compete with glutamine for transport 
in these cells. 
Effect of MSO on IL-12 secretion 
Our lab has previously shown that mice treated with MSO show a significant reduction in 
plasma IFNγ after being infected with lipopolysaccharide and D-galactosamine(35). Peritoneal 
macrophages generate IL-12, the major inducer of the Th1 T lymphocyte subclass that produces 
IFNγ during infection. Therefore, we tested the effects of MSO on IL-12 production in isolated 
macrophages to assess whether the observed in vivo decrease of IFNγ after MSO treatment could 
be attributed to a reduction in macrophage-produced IL-12. Preliminary data, shown in Table 7, 
suggest that MSO treatment can reduce IL-12 secretion by mouse peritoneal macrophages after 
being exposed to LPS for 24 hours. The results describe two independent macrophage populations; 
replication of the experiment is necessary to determine whether this effect is statistically 
significant. 
71 
 
 
 
IL-12 (pg/mL) 
Sample LPS LPS +MSO Untreated 
1 58.96 41.68 0 
2 88.60 43.40 0 
Table 7. Effect of MSO treatment on IL-12 secretion. In two independent samples, MSO 
treatment reduced the concentration of IL-12 secreted into the medium by peritoneal macrophages 
stimulated with LPS for 24 hours (29% for and 52% for Samples 1 and 2, respectively). Untreated 
cells did not produce measurable levels of IL-12. The effect of MSO alone (minus LPS) was not 
tested on these cells. 
 MSO can bind to Eukaryotic elongation factor 1 alpha 1 (eEF1A1) 
 In order to identify other possible targets of MSO, we covalently linked the N-terminus of 
racemic MSO, L,S-MSO, and L,R-MSO to N-hydroxysuccinimide linked beads and performed 
pull-down assays. Figure 13 shows a unique protein that was pulled down by all three MSO 
mixtures but not with the polyethanolamine control. The gel presented in Figure 13 was submitted 
to the Wayne State Proteomics Core Facility and the protein band was identified as eukaryotic 
translation elongation factor 1 alpha 1 (eEF1A1). Eukaryotic translation elongation factor 1 alpha 
1 has been verified as a functional regulator of IL-6 production in human astrocytes(134). 
However, the MSO gel suspensions did not bind to glutamine synthetase, the known target of 
MSO. Furthermore, cross-linking MSO to a solid support eliminates the positive charge on the 
amino terminus, altering the structure of MSO and potentially altering the binding specificity. 
Therefore, further investigation must be performed before EEF1A1 can be validated as a functional 
target of MSO. 
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Figure 13. MSO can pull-down eEF1A1. SDS-PAGE gel result of an MSO pull-down 
experiment. All 3 formulations of MSO pulled down a 50 kD protein, that was not pulled down by 
a polyethanolamine sample. 
M = molecular weight marker; L = rat liver lysate; C = polyethanolamine control; R,S-
MSO = racemic MSO; S = L,S-MSO, R = L,R-MSO 
Discussion and Conclusions 
 Preliminary data from our lab have provided insight towards potentially novel functions of 
MSO and have taught important lessons on the practicality of designing future experiments to 
elucidate new targets of MSO. These data suggest that 1) MSO might compete with glutamine for 
transport into peritoneal macrophages, 2) MSO may also inhibit IL-12 along with IL-6 and TNFα, 
and 3) MSO may bind eEF1A1, a translation factor which could potentially add weight to our 
hypothesis that MSO acts at the level of translation. However, each one of these experiments must 
be repeated several times and specific concerns must be addressed in order to validate these results. 
As it was eluded to in Chapter 3, MSO appears to compete with glutamine for transport 
across the plasma membrane of peritoneal macrophages. However, we have only tested this effect 
with1 mM MSO, a concentration that is significantly higher than the glutamine concentrations 
used in our experiments, and this competition appears to be very weak. Several concentrations of 
MSO need to be tested to confirm that this inhibition is significant, that it is indeed competitive, 
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as well as to calculate an apparent Ki value of inhibition. Although multiple investigators have 
used liquid chromatography paired with mass spectrometry techniques to quantify the intracellular 
concentration of glutamine in LPS stimulated peritoneal macrophages(135,136) the rate of overall 
glutamine transport in peritoneal macrophages has not been effectively characterized, most likely 
because several confounding variables exist that may significantly affect the results of such 
transport experiments.  
As mentioned previously, there are over a dozen families of amino acid transporters that 
are capable of transporting glutamine across the plasma membrane of mammalian cells. 
Furthermore, several factors may influence the rate of glutamine uptake in cell culture systems, 
such as temperature and the Na+/K+ concentrations in the uptake media. Our data suggest that 
glutamine concentrations exceeding 4 μM are needed to saturate the rate of glutamine transport. 
Lastly the homeostatic plasma glutamine concentration is in the millimolar range, so it is likely 
that very high concentrations of glutamine are needed to saturate the transport reaction. We tried 
to keep the specific activity the same for all of our transport experiments, requiring changes in the 
amount of isotope added at each glutamine concentration. Therefore, testing large concentrations 
of glutamine would require using an impractical amount of isotope. Considering these concerns, 
we feel it would be more practical to perform these experiments using radiolabeled MSO rather 
than labeled glutamine.  
Regarding the effect of MSO on IL-12 secretion, we are confident that this effect is 
repeatable and noteworthy but that we must increase our sample size for the sake of statistical 
significance. In two independent samples, MSO treatment resulted in a decrease of IL-12 
compared to LPS only controls that ranged from 20-45 percent. When MSO is injected into mice 
prior to the injection of LPS, these mice show significant decreases in the IFNγ, which is produced 
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predominately by IL-12 stimulated T lymphocytes during the inflammatory response. We believe 
this in vivo result can be partly explained by a significant reduction in macrophage generated IL-
12. Lastly, since IL-23, another pro-inflammatory cytokine, shares the p40 subunit of IL-12 
detected with our ELISA kit, it is possible that MSO could also reduce IL-23 secretion. 
In addition to the benefits of using radiolabeled MSO for transport studies, we believe it 
will also provide a more suitable approach for identifying putative targets of MSO. Since MSO is 
a small molecule, we assume the probability of this molecule having multiple targets would be 
higher than what would be expected for a larger, bulkier molecule or protein. Although the 
literature is quite sparse, often involving a single study, other targets of MSO have been reported 
in various cell types, such as ornithine decarboxylase(137), histamine N-methyltransferase(138), 
and the mammalian target of rapamycin(139). We have identified eEF1A1 as a possible binding 
partner of MSO. However, we have had variable success in reproducing our original results to a 
satisfactory level. Binding MSO to a solid substrate such as Affi-Gel or other commercially 
available probes ultimately alters the molecular structure and net charge of MSO. As it is an amino 
acid, MSO is zwitterionic at physiological pH. Therefore, we believe using radiolabeled MSO 
would be a more suitable approach since it would not alter the size, structure, nor would it affect 
the net charge. A hypothetical experiment would involve the following steps: 1) incubating [14C] 
labeled MSO with a tissue lysate, 2) performing gradient centrifugation to isolate subcellular 
fractions containing the highest amount of MSO radioactivity, 3) a purification step using size 
exclusion chromatography, 4) subjecting samples to native 2D gel electrophoresis followed by 
autoradiography to elucidate bound proteins, and 4) identification of putative targets using mass 
spectroscopy. 
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A hypothesis to explain MSO mode of action 
MSO increases cerebral transmethylations in vivo 
As mentioned in Chapter 1, MSO was initially discovered as a byproduct of methionine in 
the industrial process that bleached wheat gluten with nitrogen trichloride. In dogs and cats, MSO 
treatment was shown to induce convulsions that resemble tonic-clonic seizures observed in human 
epilepsy.  Additionally, unlike most epileptogenic agents that induce seizures immediately upon 
exposure, it takes up to 6 hours for an animal to have a seizure after MSO treatment. Thus, MSO 
became a favorable model because this pre-convulsive latency period provided researchers with a 
window of time in which biochemical events associated with the generation of seizures could be 
investigated. 
In 1975, Otto Sellinger and colleagues reported that intraperitoneal injection of MSO into 
rats resulted in significant decreases in cerebral S-adenosyl methionine (SAM)(140). SAM is the 
universal methyl group donor molecule in cellular methylation reactions performed by 
methyltransferase enzymes. MSO-induced decreases in SAM were not attributed to decreased 
synthesis of SAM, but rather an increase in SAM utilization that occurred halfway through the 
pre-convulsant period. Injection of adenosine and homocysteine thiolactone into rats, a treatment 
that produces higher than normal SAH levels, was shown to antagonize cerebral methylations and 
protect against MSO seizures(141). 
Several other studies by Sellinger provide evidence for an increased in vivo 
transmethylation flux in brain tissue after MSO treatment. In brain, the major catabolic route for 
the neurotransmitter histamine begins via methylation into 3-methyl histamine. Mice that received 
MSO prior to the intraventricular injection of [3H] histamine showed increases in [3H] 3-methyl 
histamine compared to controls that received saline(142). In vitro, MSO was shown to accelerate 
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N-methyl transferase(138). Additionally, MSO treatment lead to increased methylations of various 
tRNA species, phospholipids, and increased the total carboxymethylated protein content in rodent 
brain tissue(138). Therefore, MSO causes a hypermethylation flux within brain after 
administration in vivo. 
As previously mentioned in Chapter 1, the fact that injection of SAH or methionine can 
decrease the incidences and increase the latency of MSO seizures challenges the notion that MSO 
seizures are caused by glutamine synthetase inhibition, because neither molecule interferes with 
MSO binding to GS or affects the level of the product glutamine.  
MSO increases polyamine synthesis in rodent brain 
Since S-adenosyl homocysteine (SAH), the demethylated product of SAM, was also 
significantly decreased after MSO treatment, Sellinger also hypothesized that SAM 
decarboxylation was occurring at high rates in MSO treated mice. MSO-induced decreases in SAM 
were shown to lead to increased synthesis of the biogenic polyamines spermidine and spermine. 
In mammals, the three polyamines: putrescine, spermidine, and spermine, can be synthesized via 
two routes, of which one depends on the enzyme ornithine decarboxylase (ODC). The polyamine 
biosynthesis pathways are described in Figure 13. The ODC dependent pathway begins with the 
cleavage of arginine into ornithine and urea by the enzyme arginase. Ornithine is decarboxylated 
by ODC into putrescine. Spermidine is synthesized by spermidine synthase, which combines 
putrescine with a propyl amine group from the decarboxylated form of S-adenosyl methionine. 
Spermidine can then be converted to spermine by spermine synthetase, which also uses 
decarboxylated S-adenosyl methionine. Spermine can be converted back to spermidine through 
the formation and oxidation of an N-acetyl spermine intermediate. Likewise, spermidine can be 
converted back to putrescine through an N-acetyl spermidine intermediate. Therefore, spermidine 
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and spermine can be synthesized from putrescine synthesized through ornithine directly by ODC 
or from putrescine formed through the recycling pathway involving N-acetyl spermidine. 
 In MSO-treated mice, injection of [1,4-14C] putrescine did not result in increased levels of 
[14C] spermidine or spermine. However, injection of [3,4-14C] methionine into MSO treated mice 
lead to 50% increases in cerebral spermidine and spermine. In accordance with the fact that MSO 
depletes SAH along with methionine and SAM, this evidence suggests that SAM decarboxylation 
is increased after MSO treatment. The increase in SAM decarboxylation results in increased 
cerebral concentrations of spermidine and spermine, which rely on the level of decarboxylated 
SAM synthesized by the enzyme S-adenosyl methionine decarboxylase. However, it has never 
been tested if MSO has direct effects on S-adenosyl methionine decarboxylase activity. Although 
Sellinger showed that injection of putrescine does not result in increased spermidine or spermine 
levels after MSO treatment, MSO has been shown to increase ODC activity in rat brain. It has not 
been confirmed if MSO binds to ODC directly or if the accelerated ODC activity is a consequence 
of a rise in cellular ammonia that results from glutamine synthetase inhibition, since ODC has 
activity has been shown to increase with increasing ammonia levels.(137). In conclusion, two 
independent groups have verified that MSO treatment affects polyamine levels, but the exact 
biochemical mechanism remains unclear. 
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Figure 14. Polyamine synthesis pathways. The polyamines found in animals: putrescine, 
spermidine, and spermine are synthesized in the cytoplasm from the amino acids arginine and 
methionine. The non-proteinogenic amino acid L-ornithine is generated from arginine by the 
enzyme arginase and serves as precursor molecule for the formation of spermidine and spermine. 
Polyamines are also interconverted through the enzymatic activities of spermidine/spermine acetyl 
transferase and polyamine oxidase. The generation of spermidine and spermine requires 
decarboxylated S-adenosyl methionine to provide a propyl amino group. 
ODC = ornithine decarboxylase; PAO = polyamine oxidase; SamDC = S-adenosyl methionine 
decarboxylase; SamS = S-adenosylmethionine synthetase; SpdS = spermidine synthetase; 
SpmS = spermine synthetase; SSAT = spermine/spermidine acetyltransferase. 
Spermine inhibits macrophage activation 
Polyamines are essential molecules for life, involved in several basic biological processes 
such as growth, replication, and differentiation. In addition, the polyamine spermine has been 
shown to play an important role in resolving immune responses. When infected or dying cells are 
destroyed, they release spermine into the local tissue environment. Zhang et al. showed that 
exogenous spermine significantly reduces the production of TNFα and IL-6 by isolated 
macrophages(143). This inhibition of cytokine synthesis occurred at the post transcriptional level, 
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because the transcript levels of these proteins were unaffected by spermine treatment. Spermine 
has also been shown to reduce IL-12 secretion by peritoneal macrophages and IFNγ secretion by 
Th1 cells(144).   
Using metabolomics approaches for future research 
The effects of spermine on peritoneal macrophages are strikingly similar to those of MSO. 
Both molecules inhibit the production of the pro-inflammatory cytokines TNFα, IL-6, and IL-12. 
In the case of TNFα and IL-6, both spermine and MSO inhibit the production of these proteins at 
the post-transcriptional level. Spermine is increased in brain after MSO treatment. As previously 
mentioned, MSO treatment accelerates ornithine decarboxylase activity, although it remains 
unclear whether MSO and the enzyme interact directly. Additionally, peritoneal macrophages 
express both ODC and S-adenosyl methionine decarboxylase at appreciable levels. Therefore, it is 
possible the same phenomenon that occurs in brain after MSO treatment also occurs in these cells. 
To test this hypothesis, we propose that metabolomic analysis and direct quantification of these 
small molecules would need to be performed on isolated macrophages treated with LPS (+/-) MSO. 
Recent developments in metabolomics and bioinformatics have allowed investigators to 
perform studies involving untargeted approaches for global identification and quantification of 
cellular metabolites in LPS stimulated peritoneal macrophages(145). Our data indicate that MSO 
acts post-transcriptionally to reduce IL-6 and TNFα. Metabolomic approaches would allow us to 
quantify the intracellular concentrations of several molecules of interest including the polyamines, 
and could also potentially tell us if specific biochemical pathways are affected by MSO treatment. 
For example, such metabolomic approaches have discovered that quiescent macrophages primarily 
use oxidative phosphorylation to generate ATP, whereas LPS stimulated macrophages undergo 
metabolic reprogramming and rely heavily on aerobic glycolysis due to an overall increase in 
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metabolic demand.  We cannot rule out the possibility that MSO could act as a novel metabolite 
that interacts or interferes with the metabolic state of the cell. 
 Metabolomic analyses could also shed light on whether MSO acts indirectly on 
metabolic pathways. For example, inhibiting glutamine synthetase with the L,S isomer of MSO 
results in increases in cellular ammonia levels. Multiple proteins (including glutamine 
synthetase) have been shown to have activities that are either increased or decreased by changes 
in cellular ammonia concentrations, including monoamine oxidase, GABA 
aminotransferase(146), and catalase(147). We believe such approaches will provide the best 
opportunity to identify the consequences of MSO treatment on the cellular metabolome. 
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The glutamine synthetase inhibitor methionine sulfoximine (MSO), shown previously to 
prevent death caused by an inflammatory liver response in mice, was tested on in vitro production 
of cytokines by mouse peritoneal macrophages triggered with lipopolysaccharide (LPS). MSO 
significantly reduced the production of Interleukin 6 (IL-6) and Tumor Necrosis Factor Alpha 
(TNFα) at 4 and 6 hours after LPS-treatment.  This reduction did not result from decreased 
transcription of IL-6 and TNFα genes, and therefore appeared to result from post-transcriptional 
inhibition of synthesis of these cytokines.  MSO treatment did not inhibit total protein synthesis 
and did not reduce the production of a third LPS-triggered cytokine CXCL1, so the effect was not 
a toxic or global downregulation of the LPS response.  The anti-inflammatory effects of a 
glutamine synthetase inhibitor were seen even though the medium contained abundant (2 mM) 
glutamine, suggesting that the target for this activity was not glutamine synthetase.   In agreement 
with this hypothesis, the L,R isomer of MSO, which does not inhibit glutamine synthetase and was 
previously thought to be inert, both significantly reduced IL-6 secretion in isolated macrophages 
and increased survival in a mouse model for inflammatory liver failure. Our findings provide 
evidence for a novel target of MSO. Future attempts to identify the additional target would 
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therefore also provide a target for therapies to treat diseases involving damaging cytokine 
responses. 
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